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Summary 
To date, four principal classes of opioid peptide receptors, μ (MOP), κ (KOP), δ (DOP) and ORL-
1 (NOP) have been identified and cloned. The experimental and clinical importance of this 
receptor family has been amply demonstrated in many diseases, though historically they have 
mainly been associated with antinociception (pain relief). The current work described herein 
discusses the impact of opioid systems on movement disorders, namely Parkinson’s disease (PD). 
PD is a relatively common neurological disease in which the motor symptoms result from the 
death of a particular dopamine (DA) containing cell population in the substantia nigra pars 
compacta (SNc). This inevitably results in a dysregulation of the activity of basal ganglia (BG); a 
set of midbrain structures responsible for normal movement programming and execution. The BG 
structures highly express opioid receptors and their endogenous peptides and, throughout the 
course of PD, opioidergic transmission appears dysregulated. The view that opioids are involved 
in compensatory or pathogenic mechanisms following loss of DA neurons lends support to the 
notion that they may represent a suitable target for the treatment of PD.  
The work contained herein describes the benefits of opioid receptor ligand administration under 
physiological or pathological conditions (e.g. in experimental models of PD). For instance, we 
discovered that the endogenous MOP receptor peptide endomorphin-1 (EM-1), when injected or 
perfused into the substantia nigra pars reticulata (SNr) of naïve rats facilitates and inhibits 
spontaneous locomotion depending on dose.  
Additionally, we have tested DOP receptor agonists in an experimental model of PD (i.e. 6-
hydroxydopamine hemilesioned rats). These studies demonstrated the ability of the selective non-
peptide DOP receptor agonist SNC-80 to alleviate symptoms in experimental PD, such as akinesia 
and poor coordinated movement. We have also showed that when administered systemically, the 
novel peptide agonist UFP-512 causes both facilitation and inhibition of movement depending on 
the dose used. Lastly, we demonstrated a functional relationship between NOP and DOP receptors 
in SNr. We showed that in SNr, blockade of NOP receptors with the selective antagonist J-113397 
and activation of DOP receptors with SNC-80 synergistically enhances motor performance in 
experimental PD. In addition to demonstrating the behavioral outcome of opioid receptor 
stimulation or blockade on a variety of movement-related parameters, we have correlated these 
behaviors with novel neurochemical findings in each of the presented studies. The overall findings 
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of the work presented shed additional light on the subject of opioidergic systems and movement 
disorders and may contribute to future therapeutics for diseases such as PD. 
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1. INTRODUCTION 
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1.1 Opioids and their receptors 
The word opium is derived from the Greek name for ‘juice’; the drug being obtained from the 
secretions of the poppy plant, Papaver somniferum. Cultivation of opium poppies for food, 
anaesthesia, and ritual purposes dates back to at least the Neolithic Age. The Sumerian, Assyrian, 
Egyptian, Greek, Roman, Persian and Arab Empires each made widespread use of opium, which 
was the most potent form of pain relief then available, allowing ancient surgeons to perform 
prolonged surgical procedures. Opium has been mentioned in the most important medical texts 
of the ancient world. By the middle of the 16th century, opium’s uses were fairly well understood 
and in the 18th century opium smoking became popular while its overuse by some individuals 
became more evident. 
Opium contains two main groups of alkaloids. Phenanthrenes, including morphine, codeine, and 
thebaine, are the main narcotic constituents of the plant. Isoquinolines such as papaverine on the 
other hand have no significant effect on the central nervous system (CNS). In 1805, the German 
pharmacist Friedrich Wilhem Adam Sertürner reported the isolation of a pure substance in opium 
that he named morphium, after Morpheus, the god of dreams. Incidentally, this was the first ever 
extraction of a pure medicinal substance from plant material. Morphine is by far the most 
prevalent and important alkaloid in opium, constituting 10-16% of the total alkaloid amount, and 
is mainly responsible for its effects such as pain relief, euphoria, addiction, lung edema and 
respiratory difficulties. 
The existence of receptors for opiate drugs was proposed by Beckett and Casy in 1954 based on 
their studies on structure-activity relationships for antinociceptive (e.g. the ability to relieve pain) 
activity in a series of synthetic opiates (Beckett and Casy, 1954). These receptors were called 
‘opioids’ since it was understood that their endogenous ligands were peptides with effects 
resembling those of opiate drugs. As early as 1965, based on structure-activity analysis studies, 
Portoghese proposed the existence of more than one opioid receptor type or the possibility of 
multiple modes of interaction between ligands and opioid receptors (Portoghese, 1965). The first 
clear evidence that opioid receptors were in fact a diverse population was presented by Martin 
and colleagues in 1976 (Martin et al., 1976). Extensive pharmacological studies since that time 
have led to the identification of four opioid receptor types based on their diverse 
pharmacological actions. The earliest proposed receptor types were named after drugs used 
during the identification process such as the µ (mu for morphine) and κ (kappa for 
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ketocyclazocine) receptors (Martin et al., 1976). Those findings clearly linked both analgesia and 
addictive properties with functions of the µ receptor. Pharmacological analysis of opioid peptide 
effects in guinea pig ileum and mouse vas deferens led to the proposal of a third opioid receptor 
named the δ (delta for vas deferens) receptor (Lord et al., 1977). Since their discovery, the 
nomenclature used to refer to these receptors has changed multiple times. According to the 
International Union of Basic and Clinical Pharmacology (IUPHAR), µ is currently referred to as 
mu opioid peptide (MOP) receptor, κ is kappa opioid peptide (KOP) receptor and δ is referred to 
as delta opioid peptide (DOP) receptor. The most recent addition to the opioid peptide family is 
the nociceptin/orphanin FQ peptide (NOP) receptor which has high sequence homology 
compared to classical opioid receptors, particularly the KOP receptor (Bunzow et al., 1994). The 
endogenous ligand of this receptor was first described by Meunier at the International Narcotics 
Research Conference in 1995 who subsequently reported the ability of this peptide, which he 
named nociceptin, to decrease forskolin-stimulated cAMP production, in vitro (Meunier et al., 
1995). A peptide of identical sequence isolated in pig brain was reported simultaneously by 
Reinscheid and colleagues (Reinscheid et al., 1995), who named it orphanin F/Q (OFQ). For the 
purposes of this text, the nomenclature used to describe the peptide and its receptor will be 
nocicpetin/orphanin FQ (N/OFQ) and the nociceptin/orphanin FQ peptide (NOP) receptor, 
respectively. 
Opioid receptors are part of the G protein-coupled receptor superfamily and are composed of 7 
hydrophobic transmembrane domains which couple to specific GTP binding proteins (G 
proteins). These G proteins are heterodimeric proteins consisting of three distinct subunits, α, β 
and γ. Opioid receptors are known to couple to Gi (Hawes et al., 2000). Through their 
intracellular actions, opioids are also known to inhibit the formation of cAMP, close voltage 
sensitive Ca2+ channels and enhance outward K+ conductance (Hawes, et al., 2000). The sum of 
these actions and their ability to reduce neurotransmitter release and neuronal excitability make 
the opioids primarily inhibitory molecules. Since their discovery, opioid peptide systems have 
been implicated in variety of diseases and treatments ranging from pain and addiction to mood 
and movement disorders based on their locations and actions in the CNS.   
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1.2 Basal Ganglia 
 The basal ganglia (BG) are a group of subcortical brain structures which control the planning and 
execution of motor programs. The BG include the striatum, globus pallidus (GP), subthalamic 
nucleus (STN) and substantia nigra (SN). The dorsolateral part of the striatum (DLS) is 
positioned along motor circuits where it integrates inputs arriving from thalamus and 
somatomotor areas of the cortex. The DLS then, in turn, modulates the output structures of BG. 
In primates (human and non human), the GP is divided into external (GPe) and internal (GPi) 
segments. In rats, these structures are represented by GP and entopeduncular nucleus (EN), 
respectively. For the purposes of this text, GPe will be referred to as GP. The SN is also 
organized into two closely linked segments, the substantia nigra pars compacta (SNc) and the 
substantia nigra pars reticulata (SNr). The disruption of coherent information flow between these 
structures results in altered output and disturbed motor activity. The primary neurotransmitters of 
the BG are γ-amino butyric acid (GABA), glutamate (GLU) and dopamine (DA). GABA being 
the main inhibitory amino acid neurotransmitter in the CNS, GLU being the main excitatory one 
and DA, depending on which receptor type it activates, may cause inhibitory (D2-like) or 
excitatory responses (D1-like). Two primary pathways (direct and indirect) are described in the 
current simplified model of BG function (Albin et al., 1989, Delong, 1990) and these two 
pathways oppositely modulate the activity of BG output structure (GPi/SNr). These output 
structures send inhibitory GABAergic projections to the thalamus in effect controlling inhibition 
and disinhibition of thalamo-cortical projections; the end result being the coordinated execution 
of motor programs. The striatum is the major input target of projections arriving to the BG.  For 
instance, extensive GLUergic inputs arrive from the cortex as well as the thalamus (Smeal et al., 
2008, for review see Smith et al., 2004) while DA arrives via SNc DAergic projections. About 
95% of striatal neurons are GABAergic medium-sized spiny neurons (Chang et al., 1982). The 
remaining neurons found in the striatum are interneurons containing either GABA or 
acetylcholine (ACh), which act to modulate the activity of the striatofugal pathways (direct and 
indirect pathways; for review see Pisani et al., 2007). 
1.21 Direct Pathway 
The direct pathway originates from one population of medium-sized spiny striatal GABAergic 
neurons which project directly to the GPi/SNr. This cell population mainly express DA D1 
receptors where DA stimulation is responsible for facilitating their activity and causing the 
 5
release of GABA and its co-transmitters, dynorphin and substance P, in SNr/GPi (for review see 
Albin et al., 1989). GPi/SNr then sends GABAergic projections to the ventromedial and 
ventrolateral thalamus (Kha et al., 2001) and excitatory (GLUergic) projections from the 
thalamus arrive in the cortex. The cortex excites the striatum which then inhibits the GPi/SNr 
through this pathway. The GPi/SNr is normally tonically active and inhibitory to the thalamus. 
When the GPi/SNr is inhibited, the thalamus is relieved from inhibition (disinhibition) and 
excites the cortex, thereby reinforcing the desired movement (Deniau and Chevalier, 1985). 
1.22 Indirect Pathway 
In the indirect pathway, a separate group of medium-sized spiny striatal GABAergic neurons 
project to GP. These striato-pallidal projections use ENK as a co-transmitter. DA D2 receptors 
are mainly expressed on this population and DA stimulation is responsible for suppressing their 
activity (Albin et al., 1989). GP then sends GABAergic projections to STN, while the STN 
projects to GPi/SNr using the excitatory neurotransmitter, GLU. The GPi/SNr projects to 
thalamus using GABA and the thalamus projects back to the cortex also using GLU. Therefore, 
the cortex excites the striatum which then inhibits GP. Since GP is inhibitory to the STN, the 
STN then becomes more active and excites the GPi/SNr. The GPi/SNr being more active then 
inhibits the thalamus thereby dampening excitation to cortex. In this way, activation of the 
indirect pathway through striatum causes a relative inhibition of movement. 
1.23 Summation of pathways 
The opponent parallel pathway hypothesis emphasizes two major paths of information flow from 
the striatum to the basal ganglia output nuclei: GPi/SNr (in primates) or EN/SNr (in rodents). 
One is an inhibitory direct pathway from the striatum to the GPi/SNr. The other is an effectively 
excitatory multisynaptic pathway from the striatum to GPi/SNr. This hypothesis suggests that the 
two pathways are in balance such that increased activity in the direct pathway causes decreased 
GPi/SNr output, and increased activity in the indirect pathway causes increased GPi/SNr output. 
These two pathways converge on the same cells in the GPi/SNr which ultimately allows for the 
precise control over BG output needed under normal conditions. By adjusting the balance, the 
cortical targets of the basal ganglia can be facilitated or inhibited. The hypothesis predicts that 
abnormally decreased output results in excessive movement (chorea) and abnormally increased 
output results in decreased movement (Parkinson’s disease).                                                                                    
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                                                                                                             (adapted from Carlson 1998, pg 244) 
Fig. 1 The anatomical organization of the basal ganglia in the human brain (left).  Shows BG 
circuitry in the human brain where the red lines indicate inhibitory input and the blue lines indicate 
excitatory input (right). The yellow accompanying lines refer to the indirect pathway (striato-
pallidal) and the green one refers to the direct pathway (striato-nigral). 
 
1.3 Opioids in the Basal Ganglia  
Opioid ligands regulate the release of various neurotransmitters in the CNS. The predominant 
inhibitory effects of opioids on neurotransmitter release was discovered in the 1950’s by studies 
demonstrating that opiates inhibit ACh release from electrically stimulated guinea pig ileum 
(Paton, 1957, Schaumann, 1957), followed by brain in vivo (Beleslin and Polak, 1965) and then 
brain slices (Sharkawi and Schulman, 1969). Since that time, opioids have also been shown to 
inhibit the release of other neurotransmitters such as noradrenaline (Montel et al., 1974), DA 
(Loh et al., 1976) and GABA (Kondo and Iwatsubo, 1978). The BG have one of the highest 
levels of endogenous opioids and opioid receptors in the brain (Peckys and Landwehrmeyer, 
1999). All opioids have been shown to regulate DA functions in different ways and their net 
effect on transmitter stimulation or inhibition depends on the anatomical localization of their 
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receptors. An additional layer of complexity to their modulatory effects is based on the fact that 
opioid receptors may be located presynaptically, which is the typical scenario, or 
postsynaptically. In the BG, opioid ligands are found in cells containing other classical 
neurotransmitters such as GABA where they act to modulate transmitter release through their 
inhibitory actions. Striatal GABAergic neurons comprising the indirect pathway (projecting to 
GP) express preproenkaphalin-A (PPE-A) whereas striatal neurons of the direct pathway 
(projecting to SNr) express preproenkephalin-B (PPE-B). Each PPE-A molecule gives rise to 6 
copies of methionine-enkephalin (met-ENK) and one copy of leucine-enkephalin (leu-ENK). 
These ENK are considered the endogenous ligands for the DOP receptor. For the purposes of this 
text, both leu-ENK and met-ENK will be referred to collectively as ENK. In the BG, ENK are 
almost exclusively found in striato-pallidal projections (indirect pathway) along with GABA. 
The direct pathway, on the other hand, is known to express and release substance P and 
dynorphin, the endogenous ligand of the KOP receptor.  
 
Opioid Receptor Type Localization 
MOP      Striatum, GPe, GPi, STN, SNr and SNc 
DOP      Striatum, GPe, GPi, STN and SNr 
KOP      Striatum, GPi, SNr and SNc 
NOP      GPe, STN, SNc and SNr 
Fig 2. Localization of opioid receptors in BG based on evidence from binding and mRNA expression 
studies (Mansour et al., 1995, Neal et al., 1999). 
 
1.4 Parkinson’s Disease 
In 1817, James Parkinson described in his monograph ‘An essay on the shaking palsy’ a severe 
movement disorder which he called paralysis agitans, later to be named Parkinson’s disease 
(PD). PD is also called "primary parkinsonism" or "idiopathic PD" (classically meaning having 
no known cause). PD is a relatively common disease affecting 0.1% of the world’s population 
with a prevalence of 1% of the population above 60 years old. Its prevalence increases 
exponentially from 1% to 5% of the population between 65 and 90 years of age. The cause of the 
disease is largely unknown and it appears to be without genetic linkage in 90-95% of cases. In 
those cases, it may be caused in part by the combination of genetic susceptibilities and 
environmental factors (Lim et al., 2002). While most forms of parkinsonism are idiopathic, 
secondary cases may result from toxicity most notably from drugs, head trauma, or other medical 
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disorders. Carlsson and colleagues (1957) experimentally showed that DA loss was a crucial 
factor underlying the pathological behaviors of PD by depleting catecholamines in mice using 
reserpine. Following this milestone discovery, DA deficiency was identified in parkinsonian 
patients (Hornykiewicz, 1966). It is now understood that PD is a progressive neurodegenerative 
disease which occurs from the loss of DA and non DA neurons in the brain. Nevertheless, PD 
motor symptoms are caused by the death of SNc DA neurons resulting in a severe reduction in 
DA at nerve terminals in the caudate nucleus and putamen (e.g. striatum level) as well as in other 
areas such as GP and STN. However, motor symptoms appear only when the level of 
degeneration exceeds the critical threshold of 70-80% of nerve terminals and around 50% of 
midbrain DA containing neurons. This disturbance in BG function results in the dysregulation of 
movement control leading to tremors, postural instability, rigidity and slowness to initiate 
(akinesia) and execute (bradykinesia) movements.  
Typically, a patient is diagnosed based on medical history and neurological examination 
conducted by interviewing and observing the patient and applying the Unified Parkinson's 
Disease Rating Scale which assesses a patient’s behaviors, mood, activity and motor behaviors. 
Early signs and symptoms of PD may sometimes be overlooked as the effects of normal aging. 
Due to symptom overlap with other diseases, only 75% of clinical diagnoses of PD are 
confirmed to be idiopathic PD at autopsy (Gelb et al., 1999). The physician may need to observe 
the person for some time until it is apparent that the symptoms are consistently present. Usually 
doctors look for shuffling of feet and lack of swing in the arms since these are hallmark 
symptoms of the disease. 
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(adapted from Brain-Mind Institute LEN) 
Fig 3. A normal (left) and a DA denervated (right) nigro-striatal tract as seen in PD. Note the 
pigmentation due to a build up of melanin in SNc is markedly darker in the normal brain compared to the 
parkinsonian brain. The loss of DA neurons in SNc results in altered BG signaling and motor 
complications. 
 
 
Fig 4. Normal BG inputs and outputs (left) and dyregulated BG inputs and outputs as a result of DA 
denervation in SNc (right). Lack of DA stimulation in striatal areas causes an increase in GABA release 
(via lack of inhibitory D2 tone) to GPe and a decrease (via lack of excitatory D1 tone) in striato-nigral 
GABA release. Ultimately the disinhibition of nigro-thalamic output is followed by reduced GLUergic 
thalamo-cortical drive.  
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1.5 Parkinson’s Disease Treatment Options 
Currently, there is no cure for PD, though there are several treatment options that can alleviate 
symptoms of the disease and improve quality of life of patients. The ‘gold standard’ 
symptomatic treatment is 3,4-dihydroxyphenylalanine (L-DOPA) which was discovered in the 
late 1960’s (Cotzias et al., 1967). L-DOPA crosses the blood brain barrier (BBB) when 
administered orally then is converted to DA by the enzyme L-aromatic amino acid 
decarboxylase. In order to avoid peripheral decarboxylation, L-DOPA is combined with a 
decarboxylase inhibitor (Carbidopa or Benserazide) which cannot cross the BBB, limiting its 
effects to the brain. The net effect of L-DOPA is the replacement of the absent DA in the nigral 
projections. L-DOPA therapy revolutionized the treatment of PD, providing dramatic benefits to 
nearly every patient who received it. This treatment is still currently the most widely used and 
provides satisfactory relief of parkinsonian symptoms for 5-10 years. However, within 5 years, a 
series of complications begin to develop in more than 40% of PD patients who receive L-DOPA 
(Ahlskog and Muenter, 2001). These side effects are the “on-off” phenomenon and abnormal 
involuntary movements (known collectively as dyskinesias). The “on-off” phenomenon refers to 
the response to L-DOPA either being good (on) or poor (off) and the overall reduction in the 
duration L-DOPA efficacy. The prevalence and severity of dyskinesias increases with the 
duration and severity of the disease (Colosimo and De Michele, 1999, Grandas et al., 1999). 
After 10 years of L-DOPA treatment, dyskinesias have developed in 70-80% of patients and in 
nearly 100% of patients whose disease onset was below the age of 45-50 years old (Quinn et al., 
1987). L-DOPA therapy can also cause non-motor complications such as hallucinations and 
psychosis (Nausieda et al., 1984, Kuzuhara, 2001) as well as loss of impulse control (Stamey and 
Jankovic, 2008).  
In addition to L-DOPA, DA D2/D3 receptor agonists (typically ropinirole or pramipexole), which 
stimulate DA receptors directly without the need for metabolic conversion, are also regularly 
used to treat PD, either alone or in conjunction with L-DOPA therapy. These agonists are not as 
effective as L-DOPA in relieving PD motor symptoms, however, their addition to L-DOPA 
therapy can significantly reduce dyskinesias (Calne, 1993). Alternative treatments have been 
used with varying degrees of success such as GLU antagonists (Kornhuber et al., 1991), 
monoamine oxidase inhibitors (Birkmayer et al., 1975), catechol-O-methytransferase inhibitors 
(Ruottinen and Rinne, 1998) and cholinergic antagonists (Duvoisin, 1967). Beside 
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pharmacological treatment, some surgical procedures have been performed on PD patients. For 
example ablative surgeries (i.e. pallidotomy or thalamotomy) or deep brain stimulation (DBS) of 
the thalamus, GPi or STN. The aim of pallidotomy and DBS is to reduce the excessive inhibitory 
output from the GPi and SNr (Hill et al., 2000). Taken together, it is clear that the currently 
available treatments for PD are lacking in some key areas such as therapeutic longevity and side 
effect profiles. For these reasons, investigators continue to search for alternative therapies with 
an emphasis on neuroprotective agents to slow or halt the progression of the disease.  
 
1.6 Opioids and Parkinson’s Disease 
PD is classically associated with degeneration of nigro-striatal DA cells although the 
involvement of other factors such as opioid systems have received more attention in the past two 
decades in an attempt to elucidate the pathophysiology of PD and L-DOPA induced dyskinesias. 
Interestingly, opioid receptors and their endogenous ligands are present in high concentration in 
the BG (Gramsch et al., 1979, Emson et al., 1980, Zamir et al., 1984, Mansour et al., 1995) and 
alterations in endogenous opioids have been reported in postmortem brain from PD patients 
(Taquet et al., 1983, 1985, Sivam, 1991). Opioid receptor agonists and antagonists have also 
been shown to affect the behavior of parkinsonian patients (Trabucchi et al., 1982, Sandyk and 
Snider, 1986, Groppetti et al., 1990). Most of these investigations have emphasized striatal 
opioid pathways in the pathological process of PD although several more recent observations 
suggest the likely importance of opioids in other areas of BG such as SNr, SNc and STN (Shen 
and Johnson, 2002, Marti et al., 2004, Aubert et al., 2007, Mabrouk et al., 2008). Antagonizing 
excitatory amino acid neurotransmission in the output structures of the BG can alleviate 
symptoms of experimental parkinsonism (Klogether and Turski, 1990, Brotchie et al., 1991). 
Since opioids are generally inhibitory in nature and localized in output structures of the BG, this 
has led investigators to consider the endogenous opioid system a viable target for the treatment 
of PD.  
 
1.61 MOP Receptors and Parkinson’s Disease 
Preclinical and clinical research into the relationship between MOP receptors and PD has been 
scarce, probably due to the evident unwanted side effects associated with MOP receptor 
stimulation (e.g. addiction, euphoria and respiratory impairments). Despite this, it is well known 
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that MOP receptors are highly expressed in several BG structures and the nigro-striatal DA 
system (Mansour et al., 1995). In non parkinsonian animals, MOP receptor agonists are known to 
stimulate locomotion when given at lower doses while higher ones cause sedation (Iwamoto, 
1981). In fact selective MOP receptor stimulation in SNr (Bontempi and Sharp, 1997) facilitates 
spontaneous locomotion and turning behavior in rats. This effect on locomotion has been 
correlated with the effect of MOP receptor stimulation on DA release in striatal areas (Di Chiara 
and Imperato, 1988) and control of GABAergic nigro-thalamic output neurons (Waszczak et al., 
1984). However, studies using the non selective MOP receptor agonist morphine in experimental 
PD has been shown to be ineffective in enhancing the antiparkinsonian effects of DA agonists 
(Samadi et al., 2004). Interestingly though, morphine has been shown to reduce the dyskinetic 
response elicited by L-DOPA in animal models of PD (Samadi et al., 2004) as well as in PD 
patients (Berg et al., 1999).  
 
1.62 KOP Receptors and Parkinson’s Disease 
The endogenous opioid peptide ligand for the KOP receptor is dynorphin. Studies examining the 
result of DA depletion on dynorphin precursor PPE-B mRNA expression have shown that it is 
descreased (Gerfen et al., 1990) in striato-nigral neurons. Dynorphin serves as a co-transmitter in 
DA D1 expressing striatal GABAergic projection neurons extending to the SNr (direct pathway). 
Additionally, the KOP receptor is found in abundance in both GP and SNr (Haber and Watson, 
1983, Mansour et al., 1993). Indeed, prodynorphin peptide immunoreactivity is dense in the SNr 
but is virtually absent in the SNc (Vincet et al., 1982). Likewise, KOP receptors are localized in 
the rat SNr but are not detectable in SNc (Mansour et al., 1987), placing this peptide receptor 
system in a strategic location to modulate the output of the BG and motor function. Despite this, 
KOP receptor agonists have been shown to produce contrasting effects compared to MOP and 
DOP receptor agonists in a number of behavioral paradigms. For instance, KOP receptor 
stimulation was shown to reduce locomotor activity in naïve mice while DOP (Ito et al., 2008) 
and MOP (Iwamoto, 1981) stimulation enhance it. Additionally, KOP receptor agonists have 
been shown to produce dysphoria in contrast to the euphoria brought about by MOP agonists 
(Mucha and Herz, 1985). Additionally, in experimental PD (6-OHDA hemilesioned rats), nigro-
striatal denervation is associated with a decrease in PPE-B mRNA expression, the precursor of 
dynorphin, in striato-nigral neurons (Gerfen et al., 1990).  Since the precursor of dynorphin may 
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be decreased in PD, investigators sought to restore dynorphin signaling using selective agonists 
with the hopes of reversing movement abnormalities caused by DA depletion. However, results 
thus far have been conflicting in terms of the potential benefit of KOP receptor agonists in the 
treatment of PD. Hughes and colleagues (1998) reported that KOP receptor agonists enadoline 
and U69,593 increased locomotion in monoamine-depleted rats. This group also demonstrated a 
synergistic effect between enadoline and L-DOPA and has suggested that KOP receptor agonists 
may have the potential as an adjunct to L-DOPA therapy in PD. On the other hand, clinical 
studies using spiradoline in PD patients by Giuffra and colleagues (1993) concluded that 
selective KOP receptor stimulation would not prove useful alone or in combination with L-
DOPA in the treatment of PD. Taken together, role of KOP receptors in PD is not clearly 
understood, yet further studies are warranted due to its localization profile and its ability to elicit 
behavioral responses in parkinsonian mice.  
 
1.63 DOP Receptors and Parkinson’s Disease 
The DOP receptor and its endogenous ligands, ENK are widely expressed in the basal ganglia, 
particularly in STN, striatum and, to a lesser extent, GP and SNr (Abou-Khalil et al., 1984,  
Mansour et al., 1993, Aubert et al. 2007, Hallett and Brotchie, 2007). ENK act as co-transmitters 
in striatal GABAergic neurons projecting to GP (Haber and Elde, 1981, Gerfen and Young, 
1988) where they inhibit GABA release from striato-pallidal terminals (Maneuf et al., 1994) 
thereby opposing the inhibitory postsynaptic influence produced by striato-pallidal neurons 
(Stanford and Cooper, 1999). This modulation may be relevant during PD. Indeed, striato-
pallidal neurons become pathogenically overactive following DA depletion, leading to 
overinhibition of pallido-subthalamic GABAergic and disinhibition of subthalamo-nigral 
GLUergic projections (DeLong, 1990). Consequently, PPE-A expression in striato-pallidal 
neurons increases (Young et al., 1986, Gerfen et al., 1990) possibly to attenuate exaggerated 
GABA release and compensate for motor deficits (Maneuf et al., 1994). Consistently, the DOP 
receptor agonist SNC-80 (Bilsky et al., 1995) promoted spontaneous or L-DOPA induced 
contralateral turning in 6-OHDA hemilesioned rats (Pinna and Di Chiara, 1998, Hudzik et al., 
2000) and reversed akinesia in reserpinized or haloperidol-treated rats as well as MPTP-treated 
marmosets (Maneuf et al., 1994, Hill et al., 2000, Hille et al., 2001) Based on the evidence that 
endogenous ENK inhibited K+-evoked GABA release in pallidal slices (Maneuf et al., 1994), it 
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was proposed that DOP receptor agonists attenuate parkinsonism by inhibiting GABA release 
from striato-pallidal GABAergic terminals. Recently we showed that SNC-80 attenuated 
akinesia/bradykinesia and improved overall gait ability in 6-OHDA hemilesioned rats while the 
selective DOP receptor antagonist naltrindole (NTD; Portoghese et al., 1988) exerted opposite 
effects (Mabrouk et al., 2008). SNC-80 decreased pallidal GABA as well as nigral GLU and 
GABA release, suggesting an action at the striatal, pallidal or nigral level. Moreover, only NTD 
perfusion in SNr (and not GP or DLS) prevented the antiakinetic effect of SNC-80 and its 
neurochemical correlates. Consistently, microinjections of SNC-80 in SNr (but not GP or DLS) 
replicated the antiparkinsonian effects of systemic SNC-80. These findings confirm that DOP 
receptor stimulation, either by synthetic agonists or endogenous ENK, promotes motor function 
under parkinsonian conditions but challenged the common view that DOP receptor agonists 
attenuate parkinsonism via intrapallidal mechanisms, suggesting, instead, that nigral DOP 
receptors are involved.  
 
1.64 NOP Receptors and Parkinson ’s Disease 
N/OFQ is a heptadecapeptide that structurally resembles dynorphin A. Its receptors are 
expressed in both cortical and subcortical motor areas, particularly in the DA containing neurons 
of SNc. Since the SNc degenerates during the course of PD, investigators sought to explore the 
relationship between the NOP system and motor functions. Since its discovery, the N/OFQ-NOP 
receptor system has been termed ‘anti-opioid’ since it has been shown to inhibit the effects of 
classical opioids. For instance, morphine mediated analgesia in the mouse tail flick test was 
attenuated by NOP receptor stimulation (Mogil et al., 1996, Calò et al., 1998). Additionally, 
N/OFQ was shown to suppress striatal DA release from ventral tegmental area (VTA; Murphy 
and Maidment, 1999) and SNc (Marti et al., 2004) as well as locomotor activity (Meunier et al., 
1995, Reinscheid et al., 1995) whereas MOP receptor agonists stimulate DA release by inhibiting 
intranigral (Lacey et al., 1989) or intra-VTA (Johnson and North, 1992) GABAergic 
interneurons. A link between N/OFQ and PD has been uncovered by our group. Thus 
N/OFQergic transmission was found to be upregulated in the DA-depleted SNr of 6-OHDA 
lesioned rats (Marti et al., 2005). Moreover, systemic or intranigral injections of NOP receptor 
antagonists such as J-113397 can attenuate experimental parkinsonism in 6-OHDA and 
haloperidol treated rats (Marti et al., 2004b, 2005) as well as MPTP-treated mice and nonhuman 
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primates (Viaro et al., 2008). Recent studies have also demonstrated that the deletion of the NOP 
precursor (preproN/OFQ) or NOP receptor genes gives mice partial resistance to MPTP toxicity 
and haloperidol-induced catalepsy, respectively (Marti et al., 2005). These findings have 
prompted investigators to identify novel selective NOP receptor antagonists for PD therapy. 
Indeed, a novel NOP receptor antagonist TRAP-101 was recently shown to reverse experimental 
PD in accordance with earlier findings using J-113397 (Marti et al., 2008). 
 
Precursor Peptide Amino acid sequence Main  Receptor 
Pro-enkephalin [met]-enkephalin YGGFM DOP 
(PPE-A) [Leu]-enkephalin YGGFL DOP 
    YGGFMRF  
    YGGFMRGL  
  Peptide E YGGFMRRVGRPEWWMDYQKRYGGFM  
  BAM 22P YGGFMRRVGRPEWWMDYQKRYG  
  Metorphamide YGGFMRRV-NH2  
Pro-
opiomelanocortin 
β-endorphin YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE MOP/DOP 
Pro-dynorphin Dynorphin A YGGFLRRIRPKLKWDNQ KOP 
(PPE-B) Dynorphin A (1-8) YGGFLRRI KOP 
  Dynorphin B YGGFLRRQFKVVT KOP 
  a-Neoendorphin YGGFLRKYPK MOP/KOP 
  β-Neoendorphin YGGFLRKYP KOP 
?? Endomorphin-1 YPWF-NH2 MOP 
  Endomorphin-2 YPFF-NH2 MOP 
Pro-nociceptin 
(PPN/OFQ) 
Nociceptin/orphanin 
FQ 
FGGFTGARKSARKLANQ NOP 
 
Fig 5. Most known endogenous opioids, their precusors, amino acid sequences and known receptors. 
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2. AIMS OF STUDIES 
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The main aim of the work presented in this thesis was to continue the investigations into the 
involvement of opioid receptors in physiological and pathological conditions affecting the BG, 
particularly as it relates to PD. These studies were performed in both naïve rats (Section I) as 
well as in 6-OHDA hemilesioned rats (Section II, III, IV), which is widely regarded as a reliable 
model of PD. We analyzed motor activity of animals which received various opioid ligands 
either systemically (i.p.) or directly into brain areas of interest (via perfusion or microinjections). 
In addition we correlated locomotor activity with neurochemical changes using in vivo 
microdialysis to further characterize the mechanism of action of opioid ligands on locomotor 
behavior.  
Section I. The main aim of this study was to investigate whether EM-1, the endogenous ligand of 
the MOP administered exogenously into the brain of naïve rats could control locomotor activity 
and through which mechanism this effect occurred. We then implemented the novel grid test to 
measure subtle animal behaviors in response to drug treatment such as reaction time and speed of 
movements. These findings were collected in parallel with in vivo microdialysis to collect 
neurochemical evidence which could demonstrate the brain area and neurotransmitters involved 
in the motor actions of EM-1.   
Section II. The main aim of this study was to investigate the role of DOP receptors in 
parkinsonism and, in particular, to investigate the circuitry underlying the antiparkinsonain 
actions of the DOP receptor agonist SNC-80. First, we wanted to demonstrate that this drug 
improved locomotor activity in the 6-OHDA hemilesioned rat model of PD. Following 
behavioral studies, we sought to determine the precise mechanism of action of DOP receptor 
agonist induced stimulation of locomotor behavior. We also wanted to understand how 
endogenous enkephalinergic tone might influence rat behavior. To this end we used the selective 
DOP receptor antagonist naltrindole systemically and injected into particular brain areas 
including dorsolateral striaum, globus pallidus (GP) and SNr.  
Section III. The main aim of this study was characterize the ability of the novel DOP receptor 
agonist H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512) to attenuate motor deficits in 6-OHDA 
hemilesioned rats. Since UFP-512 caused different behavioral effects compared to typical 
nonpeptide agonists such as SNC-80, we set out to determine the circuitry involved in motor 
actions of UFP-512 by using microdialysis coupled to behavioral testing. By coupling in vivo 
microdialysis with the akinesia test, we correlated motor activity with changes in GABA and 
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GLU release in GP and SNr. Moreover, to test the hypothesis that changes in locomotor behavior 
were associated with changes in nigro-thalamic transmission, amino acid release in ventromedial 
thalamus (a target of nigro-thalamic GABAergic projections) was also measured.  
Section IV. The main aim of this study was to describe potential interactions between the DOP 
and NOP receptor using behavioral techniques in 6-OHDA hemilesioned rats. Since we recently 
demonstrated that DOP receptor agonists and NOP receptor antagonists improved locomotor 
activity in experimental models of PD via nigral mechanisms, the behavioral and neurochemical 
profile of this combination was investigated following both systemic and intranigral 
administration. In order to characterize whether the observed effects were synergistic or additive, 
we tested these compounds at subthreshold and submaximal doses or concentrations. 
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3. MATERIALS AND METHODS 
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3.1 Animal Subjects 
Male Sprague-Dawley rats (150 g; Harlan Italy; S. Pietro al Natisone, Italy) were kept under 
regular lighting conditions (12 hr light/dark cycle) and given food and water ad libitum. The 
experimental protocols performed in the present study were approved by Ethical Committee of 
the University of Ferrara and adequate measures were taken to minimize animal pain and 
discomfort. 
 
3.2 6-OHDA lesioning 
Unilateral lesion of DAergic neurons was induced in isoflurane-anesthetized male rats as 
previously described (Marti et al., 2005). Eight micrograms of 6-OHDA (dissolved in 4 µl of 
saline containing 0.02% ascorbic acid) were stereotaxically injected according to the following 
coordinates from bregma: AP= -4.4 mm, ML= -1.2 mm, DV= -7.8 mm below dura (Paxinos and 
Watson, 1982). In order to select the rats which had been successfully lesioned the rotational 
model was employed (Ungerstedt and Arbuthnott, 1970). Two weeks after 6-OHDA injection, 
denervation was evaluated with a test dose of amphetamine (5 mg/kg i.p., dissolved in saline just 
before use). Rats showing a turning behavior >7 turns/min in the direction ipsilateral to the lesion 
were enrolled in the study. This behavior has been associated with >95% loss of striatal DA 
terminals (Marti et al., 2007) and extracellular DA levels (Marti et al., 2002). Experiments were 
performed approximately 6-8 weeks after lesion.  
 
3.3 Behavioral experiments 
Three behavioral tests were used to evaluate different motor functions as previously described  
(Marti et al., 2005):  the bar test (Kuschinski and Hornykiewicz, 1972; for a review see Sanberg 
et al., 1988) measures the rat ability to respond to an imposed static posture; 2) the drag test 
(modification of the “wheelbarrow test”; Schallert et al., 1979) measures rat ability to balance 
body posture using the forelimbs in response to an externally imposed dynamic stimulus (i.e. 
backward dragging); 3) the fixed-speed rotarod test (Rozas et al., 1997) measures overall motor 
performance as an integration of coordination, gait, balance, muscle tone and motivation to run.  
The three tests were repeated in a fixed sequence (bar, drag and rotarod) before (control) then 20 
and 70 min after drug injection. Motor activity was then expressed as percent of performance in 
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the control session. Rats were trained for approximately 10 days to the specific motor tasks until 
their motor performance became reproducible.  
3.31 Bar Test. Rats were placed on a table and each forepaw was placed alternatively on blocks 
of increasing heights (3, 6 and 9 cm). Total time (in seconds) spent by each paw on the blocks 
was recorded (cut-off  time 20 sec).   
3.32 Drag test.  Rats were lifted from the tail (allowing the forepaws to rest on the table) and 
dragged backwards at a constant speed (~20 cm/sec) for a fixed distance (100 cm). The number 
of steps made by each forepaw was counted by two separate observers.  
3.33 Rotarod test. The fixed-speed rotarod test was employed using an established  protocol 
(Marti et al., 2004). Briefly, rats were trained for 10 days to a complete motor task on the rotarod 
(i.e. from 5 to 55 rpm; 180 sec each) until their motor performance became reproducible in three 
consecutive sessions. Rats were then tested at 4 increasing speeds (usually 10, 15, 20, 25 rpm), 
causing a progressive decrement of performance to about 40% of the maximal response (i.e. the 
experimental cut-off time).  
 
 
Fig 6. The bar test. This test measures akinesia or time to initiate movement after an imposed static 
posture. Animal is placed on 3 separate block heights, 3, 6 and 9 cm and timed. 
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Fig 7. The drag test. This test measures rat ability to balance body posture using the forelimbs in response 
to an externally imposed dynamic stimulus (i.e. backward dragging). 
 
 
Fig 8. The rotarod test. This test measures overall motor performance as an integration of coordination, 
gait, balance, muscle tone and motivation to run.   
 
3.34 Inclined grid test. A modified version of the inclined grid test originally developed to 
evaluate catalepsy in rodents (Ahlenius and Hillegaart, 1986) was employed. A metallic grid (30 
x 45 cm) was positioned vertically in the microdialysis cage with a of 60° inclination (Fig 9). 
Rats undergoing microdialysis were placed in the upper half of the grid and left free to move 
back to the cage. Each trial started when the rat firmly gripped the grid and terminated when the 
rat touched the bottom of the cage with both forepaws and hindpaws. Rat motor behavior was 
videotaped and analyzed posthoc by an experimentally blind investigator using a VCR with slow 
motion and frame by frame (25 Hz) capabilities. Several motor parameters were recorded: i) 
latencies of head and forepaw movement (in sec) as a measure of akinesia (Reaction Time; RT); 
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ii) speed of forepaw movement (in cm/sec) and step length (cm), as a measure of forepaw 
bradykinesia and gait abnormalities. Each experimental session consisted of 8-10 trials (usually 
90-120 sec). 
 
 
Fig 9. The inclined grid test coupled to microdialysis. This test measures subtle changes in locomotor 
behavior including reaction time, speed of movements and length of forepaw steps. 
 
3.4 Microinjection technique 
Microinjections were performed as previously described (Marti et al., 2004). Microinjection 
guide cannulas (outer diameter 0.55 mm) were stereotaxically implanted under isoflurane 
anaesthesia 0.50 mm above the lesioned SNr (AP -5.5, ML -2.2, DV -7.8 from bregma, Paxinos 
and Watson 1982), GP (AP -1.3, ML -3.3, DV -6.0) and DLS (AP +1.0, ML -3.5, DV -5.5),  and 
secured to the skull by acrylic dental cement and metallic screws. Seven days after surgery, 
saline or SNC-80 (0.5 µl volume) were injected through a stainless-steel injector (outer diameter 
0.30 mm) protruding 1 mm beyond the cannula tip. In a separate set of experiments, bicuculline 
(1.5 nmol) was injected in GP. At the end of each experiment the placement of the guide cannula 
was verified by microscopic examination. 
 
3.5 Microdialysis experiments 
3.51 Probe construction 
Probes were produced using a concentric design with silica tubing (Polymicro technologies), 
polyethylene tubing (Smiths Company), stainless steel tubing (outer diameter 0.55 mm) and 
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dialysis membrane (Hospal Bologna).  Inlet portion of probes consisted of  8 cm polyethylene 
tubing combined with a 3 cm silica tube glued in place with cyanoacrylate (CA) adhesive 
(Loctite, Attack). The outlet portion of the probe consisted of a 10 cm section of polyethylene 
tube combined with a 1.5 cm section of silica tubing also glued in place. Silica tubing extended 5 
mm into polyethylene tubing when was secured with CA adhesive.  
Inlet and outlet silica/polyethylene tubing structures were left to dry and then gently inserted into 
stainless steel tubing. For SNr, GP and VMTh, the stainless steel used was 20 mm while for 
studies employee DLS probes, stainless steel was 15 mm. CA adhesive was then used to secure 
the 3 pieces together and left to dry overnight. Larger tubing was then placed around the point 
where the 3 pieces converged to further strengthen the structure and more adhesive is added at 
this site and left to dry overnight.  
The inlet portion of the probe with silica extending beyond the stainless steel was then cut to the 
desired length.  For SNr, GP, and VMTh, 1 mm was used while for DLS, 3 mm was used. 
Membrane is cut and gently inserted over the silica and then cut just beyond where silica ends. 
Using epoxy adhesive, the membrane is secured to the rest of the structure and the tip is capped 
leaving a very small space between the end of the silica tubing and the tip of the membrane.  The 
structure is then left to dry for 3 days before experiment. Probes were tested the day of use by 
pushing purified water through them while checking for any leakage. In vitro recovery for probes 
were tested periodically and consistenly offered ~10-15% recovery. 
 3.52 Surgery and microdialysis procedure 
Microdialysis probes were stereotaxically implanted, under isoflurane anaesthesia, in the DLS 
(section I), SNr (section I, II, III, IV), GP (Section II, III, IV), and VMTh (Section III and IV) 
according to the following coordinates from bregma: DLS; AP +1.0, ML -3.5, DV -6.0, SNr; AP 
-5.5, ML -2.2, DV -8.3, GP; AP -1.3, ML -3.3, DV -6.5, VMTh; AP -2.3, ML -1.4, DV -7.4. 
Probes were secured to the skull by acrylic dental cement and metallic screws. After surgery, rats 
were allowed to recover and experiments were run 24 hr after probe implantation. Microdialysis 
probes were perfused at a flow rate of 3.0 µl/min with a modified Ringer solution (composition 
in mM: CaCl2 1.2; KCl 2.7, NaCl 148 and MgCl2 0.85). Samples were collected every 15 min, 
starting 6 hr after the onset of probe perfusion. At least 4 stable values were collected before 
beginning of experiment. 
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Fig 10. A close up schematic of a microdialysis probe during perfusion (left) and a typical dual probe 
microdialysis experiment with a rat in home cage (right).  
 
Fig. 11. Example of histological verification of probe placements in SNr and GP. Black points refer to 
probe tip locations after reviewing brain slices in cryostat. 
 
3.6 Microdialysis + Bar test coupling 
The bar test was coupled to microdialysis in order to more accurately characterize the time 
course of drug effect with respect to neurochemical changes. Bar test, as described above, was 
simply performed inside microdialysis cages. Animals were handled in their microdialysis cages 
for 1 hr prior to starting the experiments. Amount of time spent on the bar was measured every 
15 minutes (duration of one sample collection) for 45 minutes prior to drug and 90-150 minutes 
after drug administration. Total time (in sec) spent by each paw on the blocks was recorded (cut-
off  time 20 sec for each block height). 
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3.7 Endogenous GLU and GABA analysis 
GLU and GABA were measured by HPLC coupled with fluorometric detection as previously 
described (Marti et al., 2007). Thirty microliters of o-phthaldialdehyde/mercaptoethanol reagent 
was added to 40 µl aliquots of sample, and 60 µl of the mixture was automatically injected 
(Triathlon autosampler; Spark Holland, Emmen, Netherlands) onto a 5-C18 Chromsep analytical 
column (3 mm inner diameter, 10 cm length; Chrompack, Middelburg, Netherlands) run at a 
flow rate of 0.48 ml/min (Beckman 125 pump; Beckman Instruments, Fullerton, CA, USA) with 
a mobile phase containing 0.1 M sodium acetate, 10% methanol and 2.2% tetrahydrofuran (pH 
6.5). GLU and GABA were detected by means of a fluorescence spectrophotometer FP-2020 
Plus (Jasco, Tokyo Japan) with the excitation and the emission wavelengths set at 370 and 450 
nm respectively. The limits of detection for GLU and GABA were about 150 fmol/sample. 
Retention times for GLU and GABA were 3.5 ± 0.2 min and 18.0 ± 0.5 min respectively.   
 
 
Fig 12. (Left) HPLC coupled to spectrofluorescence detector configured specifically for the detection of 
GABA and GLU. A) Mobile phase B) Methanol C) Pumps 1 and 2 (Beckman 125) D) Autosampler 
(Triathalon, Spark Holland) E) 5C-18 chromsep column F) HPLC system interface G) 
Spectrofluorescence detector (Jasco 2020 plus). 
(Right) A typical chromatogram showing the retention times for GLU and GABA. Concentration of 
amino acids were calculated automatically by peak height analysis. 
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3.8 Endogenous DA analysis 
DA was measured by means of reversed phase HPLC coupled with electrochemical detection. 
Briefly, 27 µl samples were injected onto a 5-C18 Chromsep analytical column run at a flow rate 
of 0.4 ml/min (Beckman 118 pump, Beckman Instruments, Fullerton, CA, USA) with a mobile 
phase containing 75 mM NaH2PO4, 20 µM EDTA, 0.01% triethylamine, 1.5 mM sodium 
dodecyl sulphate, 10% methanol and 16% acetonitrile adjusted to pH 5.6 with NaOH. DA was 
separated under isocratic conditions (~6.5 min retention time) and detected by means of an 
electrochemical detector (Coulochem II Model 5200; ESA, Inc, Chelmsford, MA, USA) set at 
+175 mV. The limit of detection for DA was 10 fmol/sample. 
 
3.9 Data presentation and statistical analysis 
Motor performance has been calculated as time on bar or on rod (in sec) and number of steps 
(drag test) and expressed as percent of the control session. In microdialysis studies, GLU and 
GABA release has been expressed as percentage ± SEM of basal values (calculated as mean of 
the two samples before the treatment). In text and Figure legends, amino acid dialysate levels 
were also given in absolute values (in nM). 
Motor activity in the inclined grid test has been calculated as time of latency to initiate 
movements of the head and left and right forepaw (in sec), velocity (in cm/sec) and step length 
(cm) of left and right forepaw and expressed as percent of the control session. Statistical analysis 
has been performed on percent data by one-way repeated measure (RM) analysis of variance 
(ANOVA). In case ANOVA yielded a significant F score, post-hoc analysis was performed by 
contrast analysis to determine group differences. In case a significant time X treatment 
interaction was found, the sequentially rejective Bonferroni test was used (implemented on excel 
spreadsheet) to determine specific differences (i.e. at the single time-point level) between groups. 
P values <0.05 were considered to be statistically significant. 
 
3.10 Materials 
EM-1, UFP-512 and J-113397 were synthesized in the laboratories of the Department of 
Pharmaceutical Sciences (University of Ferrara). CTOP, bicuculline, raclopride SCH-23390, 
NTD and SNC-80 were purchased from Tocris Neuramin (Bristol, UK). 6-OHDA hydrobromide 
and d-amphetamine sulphate were purchased from Sigma  (St. Louis, MO, USA). All drugs were 
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freshly dissolved in Ringer or isosmotic saline just before use with the exception of SNC-80. 
SNC-80 (10 mg/kg) was dissolved in saline containing 5% DMSO while other doses given 
systemically (0.1-3 mg/kg) or microinjected (0.1 and 1 nmol) only needed 0.5% DMSO. In both 
cases, vehicle alone did not affect behavioral or neurochemical responses. SNC-80 was vortexed 
and sonicated for 15 min or until fully dissolved in solution.   
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4. RESULTS 
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Section I 
The endogenous MOP receptor agonist EM-1 dually affects motor activity and 
differentially modulates nigro-striatal and nigro-thalamic pathways. 
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Behavioral Studies I 
4.1.1 Effect of i.c.v. injection of EM-1 and CTOP on motor behavior 
The effect intracerebroventricular (i.c.v.) administration of EM-1 on physiologically-stimulated 
motor activity was studied by means of the rotarod test.  
In this test, RM ANOVA showed a significant effect of treatment (F4,16=342.7, p<0.0001), but 
not time (F1,20=4.3, p=0.051) and a significant time X treatment interaction (F4,20=10.5, 
p<0.0001). EM-1 (0.01-10 nmol) biphasically regulated the rotarod performance (Fig. 13A), 
causing motor facilitation at 0.1 and 1 nmol (∼35% and ∼55%, respectively) and motor 
impairment at 10 nmol (∼90%). At this dose, EM-1 increased muscle rigidity which probably 
impaired the execution of the test.  
To unravel tonic regulation by endogenous EM-1 and also investigate the selectivity of 
exogenous EM-1, the selective MOP receptor antagonist CTOP was employed. RM ANOVA on 
the effect of CTOP alone showed a significant effect of treatment (F2,8=14.9, p=0.0019) but not 
time (F1,12=0.4, p=0.5504) and a non significant time X treatment interaction (F2,12=0.4, 
p=0.6722). CTOP was ineffective at 1 nmol and produced a long-lasting reduction in rotarod 
performance at 10 nmol (∼30%) which persisted up to 60 min (Fig. 13B). An ineffective dose of 
CTOP (1 nmol) prevented the facilitation caused by EM-1 (1 nmol; Fig. 13 C). 
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Fig 13. Effect of i.c.v. injection of EM-1 (0.01-10 nmol; A), CTOP (1 and 10 nmol; B) and their co-
administration (EM-1 1 nmol and CTOP 1 nmol; C) on rat motor performance on the rotarod. Each 
experiment consisted of three different sessions: a control session followed (40 min) by other two 
sessions performed 10 and 60 min after saline, or drug injection (see Methods). Data are expressed as 
percentages of basal motor activity in the control session and are means ± SEM of 6-8 determinations per 
group. Basal motor activity in the rotarod performance was 1044 ± 40 sec (0-55 rpm range).   
**p<0.01 significantly different from saline, 
##p<0.01 significantly different from EM-1 (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
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4.1.2 Effect of intranigral injection of EM-1 on motor behavior 
To investigate the involvement of SNr in central motor effects of EM-1, intranigral 
microinjections of EM-1 and CTOP were performed and rotarod activity evaluated.  
EM-1 (0.01-10 nmol) biphasically regulated rotarod performance (Fig. 14A). RM ANOVA 
showed a significant effect of treatment (F4,24=402.6, p<0.0001), but not time (F1,26=0.1, p=0.71) 
and a non significant time X treatment interaction (F4,26=1.4, p=0.26). Significant increases were 
observed at 0.1 and 1 nmol EM-1 (∼30% and ∼40%, respectively) while marked impairment was 
observed at 10 nmol (∼80%) at 10 min post-injection time and  persisted up to 60 min (Fig. 
14A).  
When administered in SNr, EM-1 evoked spontaneous contralateral turning (Fig. 14B). RM 
ANOVA showed a significant effect of treatment (F2,12=35.81, p<0.0001), time (F20,360=18.06, 
p<0.0001) and a significant time X treatment interaction (F40,360=16.98, p<0.0001). EM-1 
induced turning at 10 nmol, but not at 1 nmol (Fig. 14B).  
The MOP receptor antagonist CTOP modulated rotarod performance (Fig. 14C). RM ANOVA 
showed a significant effect of treatment (F2,8=14.9, p=0.0019) but not time (F1,12=0.024, p=0.87) 
and a non significant time X treatment interaction (F2,12=0.026, p=0.97). CTOP was ineffective 
at 1 nmol yet caused a prolonged reduction of rotarod performance at 10 nmol (∼30%; Fig. 14C). 
An ineffective dose of CTOP (1 nmol) prevented the facilitation of rotarod performance caused 
by EM-1 (1 nmol; Fig. 14D).  
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Fig 14. Effect of intranigral injection of EM-1 (0.01-10 nmol; A-B), CTOP (1 and 10 nmol; C) and their 
co-administration (EM-1 1 nmol and CTOP 1 nmol; D) on rat motor behavior. EM-1 was injected i.c.v. 
and motor activity evaluated in the rotarod (A) and spontaneous rotational (B) tests. Each experiment 
consisted of three different sessions: a control session followed (40 min) by other two sessions performed 
10 and 60 min after saline, EM-1, CTOP or their co-injection (see Methods). Data are expressed as 
percentages of basal motor activity in the control session and are means ± SEM of 6-8 determinations per 
group. Basal motor activity in the rotarod performance was 1020 ± 29 sec (0-55 rpm range).  In 
spontaneous rotational test data are expressed as absolute values (number of turning executed in 5 min). 
**p<0.01 significantly different from saline, 
##p<0.01 significantly different from EM-1 (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
Neurochemical studies 
4.1.3 Effect of perfusion with EM-1 in SNr on local GABA and GLU extracellular levels 
Since the behavioral data pointed to the involvement of nigral MOP receptors in the effects of 
EM-1, we investigated how local EM-1 perfusion in the SNr affected local GABA and GLU 
release. RM ANOVA on GABA levels revealed a significant effect of treatment (F4,20=9.09, 
p<0.001), time (F7,167=2.33, p<0.05), and a significant time X treatment interaction (F28,167=2.11, 
p=0.026). Post hoc analysis showed that EM-1, ineffective at 0.001 µM, produced a prompt and 
transient increase at 0.01 µM (~200% at peak) and a prompt and long lasting decrease at 1 µM 
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(~45% at the end of perfusion) while the stimulation induced by an intermediate concentration 
(i.e. 0.1 µM) was not significant (Fig. 15A).  
To test the specificity of EM-1, high EM-1 concentrations (i.e 1 µM) were challenged with 
CTOP (3 µM; Fig. 15B). For these data, RM ANOVA on nigral GABA levels revealed a 
significant effect of treatment (F3,53=9.66, p=0.0002), time (F7,23=21.05, p<0.0001) and time X 
treatment interaction (F21,429 = 12.22, p <0.0001). Post hoc analysis showed that intranigral 
perfusion with CTOP alone did not modify local GABA levels yet prevented the inhibition 
induced by EM-1 (Fig. 15B).  
Intranigral perfusion with EM-1 (0.01-1 µM; 90 min) was also associated with changes in nigral 
GLU levels (Fig. 15C). RM ANOVA on GLU levels revealed a significant effect of treatment 
(F3,17=21.42, p<0.001), time (F7,468=13.45, p<0.0001), and a significant time X treatment 
interaction (F21,468=10.68, p<0.0001). Post hoc analysis showed that EM-1, ineffective at 0.01 
µM, evoked a prompt and long lasting facilitation (~153% by end of perfusion) at 0.1 µM  and a 
prompt but short-lived increase (~189%) at 1 µM (Fig. 15C).  
Again, the specificity of EM-1 was investigated by using CTOP (Fig. 15D). RM ANOVA on 
nigral GLU levels revealed a non significant effect of treatment (F3,17=1.55, p=0.2130) but a 
significant effect of time (F7,436=14.05, p<0.0001) and time X treatment interaction (F21,436=9.82, 
p<0.0001). Intranigral perfusion with CTOP (3 µM), ineffective alone, prevented the increase in 
GLU induced by EM-1 (1 µM; Fig. 15D). 
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Fig 15. Effect of reverse dialysis of EM-1 (0.01-1µM; black bar) and CTOP (3 µM) in the substantia 
nigra pars reticulata (SNr) of awake rats on local extracellular GABA (A-B) and GLU (C-D) levels. 
Perfusion with CTOP started 90 min before EM-1 and continued until the end of experiment. Data are 
expressed as percentages ± SEM of basal pre-treatment levels (calculated as mean of the two samples 
before the treatment). Basal GABA levels in the SNr were 6.0 ± 0.6 nM while GLU levels were 132.9 ± 
13.5 nM.  
*p<0.05, significantly different from Ringer (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
Behavioral studies II 
4.1.4 Effect of intranigral perfusion of EM-1 on grid test and spontaneous motor activity 
In view of the ability of EM-1 to oppositely modulate rotarod performance and SNr GABA 
release, in a separate series of microdialysis experiments we investigated whether intranigral 
perfusion with low (0.01 µM) and high (1 µM) EM-1 concentrations was accompanied by 
opposite changes in motor activity. Rat activity was recorded by videotape at rest and during 
performance of the grid test. Different motor parameters were analyzed post hoc using video 
recordings. 
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4.1.41 Effect on neck/trunk and forepaw reaction time 
RM ANOVA on neck/trunk reaction time (RT; Fig. 16A), showed a significant effect of 
treatment (F2,12=1.75, p<0.0001), time (F7,126=15.65, p<0.0001) and a significant time X 
treatment interaction (F14,126=9.39, p<0.0001). Perfusion with the lower EM-1 concentration 
(0.01 µM) caused a prompt and long lasting reduction (~57% at 15 min) while EM-1 (1 µM) 
caused a biphasic response characterized by a transient reduction (~46% at 15 min) followed by 
a slight increase (~12% at 90 min; Fig. 16A).  
RM ANOVA on RT at the ipsilateral forepaw (Fig. 16B) also showed a significant effect of 
treatment (F2,12=12.75, p=0.0011), time (F7,126=21.59, p<0.0001) and a significant time X 
treatment interaction (F14,126=9.12, p<0.0001). EM-1 (0.01 µM) caused a prompt and transient 
reduction in RT at the ipsilateral forepaw (~59% at 15 min) while EM-1 (1 µM) caused a prompt 
decrease (~36% at 15 min) followed by a long lasting increase (~45% at 75 min; Fig. 16B).  
Finally, RM ANOVA on RT at the contralateral paw (Fig. 16C) showed a significant effect of 
treatment (F2,12=40.23, p<0.0001), time (F7,126=20.59, p<0.0001) and a significant time X 
treatment interaction (F14,126=24.35, p<0.0001). EM-1 (0.01 µM) caused a prompt and long 
lasting reduction in RT at the contralateral forepaw (~72% at 15 min) while EM-1 (1 µM) caused 
a prompt decrease (~43% at 15 min) followed by a robust and long lasting increase (~106% at 60 
min; Fig. 16C).  
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Fig 16. Effect of intranigral EM-1 (0.01-1µM) perfusion on reaction time (RT) at the neck/trunk and 
ipsilateral and contralateral forepaws in the grid test. Data are expressed as percentages ± SEM (7 
determinations per group) of basal pre-treatment levels (calculated as mean of the two samples before the 
treatment). The latency to initiate movements (reaction time, RT) after being positioned on the grid were 
(in sec): 1.1 ± 0.2 (neck and trunk torsion; A), 2.6 ± 0.4 (ipsilateral paw; B) and 2.8 ± 0.5 (contralateral 
paw; C). 
*p<0.05, significantly different from Ringer (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
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4.1.42 Effect of EM-1 on forepaw speed and gait control 
On the speed of the ipsilateral forepaw (Fig. 17A), RM ANOVA showed a significant effect of 
treatment (F2,12=151.59, p<0.0001), time (F7,126=17.30, p<0.0001) and a significant time X 
treatment interaction (F14,126=15.77, p<0.0001). Intranigral perfusion with EM-1 (0.01 µM) 
promptly increased ipsilateral forepaw speed (~69% at 15 min) while EM-1 (1 µM) was without 
effect (Fig. 17A).  
On the speed of the contralateral forepaw (Fig. 17B), RM ANOVA also showed a significant 
effect of treatment (F2,12=151.77, p<0.0001), time (F7,126=31.53, p<0.0001) and a significant time 
X treatment interaction (F14,126=33.62, p<0.0001). EM-1 (0.01 µM) caused a prompt and robust 
increase in speed of the contralateral paw (~127% at 15 min) while EM-1 (1 µM) caused a 
biphasic effect characterized by a prompt transient increase (~58% at 15 min) then a long lasting 
decrease (~46%) in contralateral forepaw speed (Fig. 17B).  
On step length at the ipsilateral forepaw (Fig. 17C), RM ANOVA showed a significant effect of 
treatment (F2,12=19.08, p=0.0002), but not time (F7,126=1.40, p=0.2108) and a significant time X 
treatment interaction (F14,126=33.62, p=0.0002). EM-1 (0.01 µM) caused a mild and transient 
increase in step length (~15% at 15 min) at the ipsilateral forepaw while EM-1 (1 µM) caused a 
mild, yet long lasting decrease (Fig. 17C).  
On step length at the contralateral forepaw (Fig. 17D), RM ANOVA also showed a significant 
effect of treatment (F2,12=17.29, p=0.0003), time (F7,126=10.99, p<0.0001) and a significant time 
X treatment interaction (F14,126=6.02, p<0.0001). Here, EM-1 (0.01 µM) caused a short-lived 
increase in step length (~28% at 15 min) while EM-1 (1 µM) caused a delayed long-lasting 
reduction (Fig. 17D).  
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Fig 17. Effect of intranigral EM-1 (0.01-1µM) perfusion on speed and step length of contralateral and 
ipsilateral forepaws in the grid test. Data are expressed as percentages ± SEM (7 determinations per 
group) of basal pre-treatment levels (calculated as mean of the two samples before the treatment). Before 
testing, forepaw speed was 0.43 ± 0.03 and 0.47 ± 0.03 cm/sec for the ipsilateral and  contralateral paw, 
respectively. Step length during movement on the grid was 6.7 ± 0.1 and 6.6 ± 0.2 cm at the ipsilateral 
and contralateral paw, respectively. 
*p<0.05, significantly different from Ringer (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
Neurochemical studies II 
4.1.5 Effect of EM-1 on neurotransmitter release in rats undergoing the grid test 
To correlate the behavioral effects of EM-1 to nigral release of GABA and GLU, we performed 
microdialysis in animals undergoing the grid test.  
RM ANOVA on GABA release (Fig. 18A) showed a significant effect of treatment 
(F2,12=154.03, p<0.0001), time (F7,126=2.10, p=0.048), and a significant time X treatment 
interaction (F14,126=7.81, p<0.0001). Post hoc analysis on nigral GABA release revealed dual 
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effects depending on concentration used where EM-1 (0.01 µM) caused an increase (~102% at 
45 min) and EM-1 (1 µM) caused a long lasting decrease (~46% at 90 min; Fig. 18A).  
RM ANOVA on nigral GLU levels (Fig. 18B) showed a non significant effect of treatment 
(F2,12=2.39, p=0.134), but a significant time (F7,126=15.87, p<0.0001), and a time X treatment 
interaction (F14,126=7.54, p<0.0001). Post hoc analysis showed that EM-1 (0.01 µM) had no 
effect while EM-1 (1 µM) transiently increased (~87% at 15 min) nigral GLU levels (Fig. 18B).  
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Fig 18. Effect of EM-1 perfusions on nigral GABA (A) and GLU (B) release of rats undergoing the grid 
test. Data are expressed as percentages ± SEM of basal pre-treatment levels (calculated as mean of the 
two samples before the treatment). Basal GABA levels in the SNr were 9.0 ± 0.8 nM while GLU levels 
were 98.1 ± 13.2 nM.  
*p<0.05, significantly different from Ringer (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
4.1.6 Effect of perfusion with EM-1 in SNr on striatal DA and thalamic GABA release 
To test whether EM-1 differentially modulates nigro-striatal DA and nigro-thalamic GABA 
transmission, low and high EM-1 concentrations were perfused in SNr, and DA release was 
monitored in DLS together with GABA release in VMTh.  
RM ANOVA on DA release (Fig. 19A) showed a significant effect of treatment (F3,24=149.10, 
p<0.0001), time (F7,153=5.41, p=0.0011), and a significant time X treatment interaction 
(F21,153=5.95, p=0.0001). Post hoc analysis revealed that EM-1 was ineffective at 0.01 µM but 
caused a prolonged increase in striatal DA release at 1 µM (~33% at 75 min) which was blocked 
by the co-perfusion of CTOP (3 µM; Fig. 19A).  
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RM ANOVA on thalamic GABA levels (Fig. 19B) revealed a significant effect of treatment 
(F2,12=17.46, p<0.0001), time (F7,126=7.51, p<0.0001), and a significant time X treatment 
interaction (F14,126=15.82, p<0.0001). Post hoc analysis revealed that intranigral EM-1 (0.01 µM) 
caused a long-lasting reduction in thalamic GABA levels (~39% at 45 min) while EM-1 µM 
induced a biphasic response characterized by a mild and transient reduction (~24% at 15 min) 
followed by a robust and prolonged stimulation (~99% at 90 min; Fig. 19B).  
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Fig 19. Effect of intranigral EM-1 (0.01-1µM) perfusion on DA release in DLS (A) and GABA release in 
VMTh (B). Data are expressed as percentages ± SEM of basal pre-treatment levels (calculated as mean of 
the two samples before the treatment). Basal extracellular DA levels in DLS were 1.81 ± 0.23 nM and 
basal GABA levels in VMTh were 8.0 ± 0.6 nM. Determinations for DLS DA were made from 5-8 per 
group whereas they were 7 for thalamic groups. 
*p<0.05, significantly different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
4.1.7 TTX sensitivity to modulation of EM-1 effects on nigral GABA 
We then investigated the nature of EM-1 modulation of GABA release in SNr. To determine 
whether EM-1 modulated GABA release through direct or indirect mechanisms, intranigral EM-
1 was paired with intrastriatal and/or intranigral perfusion with the Na+-dependent channel 
blocker TTX (1 µM).  
RM ANOVA on TTX perfusions against EM-1 0.01 µM (Fig. 20A) showed a significant effect 
of treatment (F5,39=22.36, p<0.0001), time (F7,23=23.234, p< 0.0001), and a significant time X 
treatment interaction (F23,237=3.55, p<0.0001). Post hoc analysis revealed that perfusion with 
TTX in DLS or in DLS and SNr reduced nigral GABA release (~40%; Fig. 20A). Moreover, the 
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increase evoked by EM-1 (0.01 µM) release was attenuated by perfusion of TTX in DLS and 
abolished in the presence of a combination of intrastriatal and intranigral TTX (Fig. 20A).  
RM ANOVA on TTX perfusion against EM-1 1 µM (Fig. 20B) showed a significant effect of 
treatment (F3,27=20.326, p<0.0001), time (F7,31=6.32, p<0.0001) and time X treatment interaction 
(F31,123=2.22, p<0.001). TTX did not reduce GABA release in SNr nor did it  prevent the 
reduction induced by EM-1 1 µM.  
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Fig 20. Effect of the voltage operated Na+ channel blocker TTX on EM-1-evoked nigral GABA 
release. Effect of reverse dialysis of TTX (1µM; 90 min) singularly in the DLS, SNr or 
simultaneously in both areas, alone or in combination with EM-1 (0.01 and 1 µM, 90 min; black 
bar) in SNr of awake rats. Perfusion with TTX started 90 min before EM-1 and continued until 
the end of experiment. Data are expressed as percentages ± SEM of basal pre-treatment levels 
(calculated as mean of the two samples before the treatment). Basal GABA levels were 7.1 ± 1.3 
nM 
*p < 0.05 different from Ringer 
°p<0.05 different from EM-1 + TTX in DLS (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
 
4.1.8 Modulation of EM-1 effects on nigral GABA by DAergic and GABAergic antagonists 
To investigate the involvement of GABAergic and DAergic mechanisms on extracellular GABA 
release in SNr, EM-1 (0.01 and 1 µM) was perfused in combination with the GABAA receptor 
antagonist bicuculline (3 µM), the D1-like receptor antagonist SCH23390 (0.1 µM) and the D2-
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like receptor antagonist raclopride (1 µM). None of these compounds alone affected local GABA 
levels (Fig. 21A).  
RM ANOVA on the effect of EM-1 (0.01 µM) on nigral GABA levels revealed a significant 
effect of treatment (F4,35=50.6, p<0.0001), time (F7,198=9.78, p<0.0001) and time X treatment 
interaction (F28,198=3.75, p<0.001). Post hoc analysis showed that EM-1 (0.01 µM) increased 
GABA release (~93%), bicuculline and raclopride prevented this effect and SCH23390 only 
reduced its duration (Fig 21B).  
RM ANOVA on EM-1 (1 µM) treatment on nigral GABA levels revealed a significant effect of 
treatment (F4,24=10.69, p<0.0001), time (F7,186=9.43, p<0.0001) and time X treatment interaction 
(F28,186=2.27, p=0.017). EM-1 (1µM) caused a long lasting decrease (~36% at 90 min; Fig. 21C). 
This effect being completely prevented by bicuculline and left unchanged by raclopride or 
SCH23390 (Fig. 21C).  
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Fig 21. Effect of perfusion of selective antagonists at GABAA, D1 and D2 receptors in SNr on EM-1-
evoked nigral GABA release. Effect of reverse dialysis of bicuculline (3 µM), SCH23390 (0.1 µM)  and 
raclopride (1 µM) alone (A) or in combination with EM-1 0.01 µM (90 min; black bar; B) or EM-1 1 µM 
(90 min; black bar; C) in SNr of awake rats. Perfusion with antagonists started 90 min before EM-1 and 
continued until the end of experiment. Data are expressed as percentages ± SEM of basal pre-treatment 
levels (calculated as mean of the two samples before the treatment). Basal GABA levels were 8.1 ± 1.6 
nM and made from 5-8 determinations per group. 
*p < 0.05 different from Ringer (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
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Section II 
Stimulation of delta opioid receptors located in substantia nigra reticulata but 
not globus pallidus or striatum restores motor activity in 6-hydroxydopamine 
lesioned rats.  
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Behavioral Studies 
4.2.1 Effect SNC-80 on motor behavior  
To investigate whether DOP receptor agonists could attenuate parkinsonian-like symptoms, 
SNC-80 was administered systemically (i.p.) and motor activity evaluated by the bar, drag and 
rotarod tests. SNC-80 (0.1-10 mg/kg) dose-dependently improved rat motor performance in all 
tests performed (Fig. 22).  
In the bar test (Fig. 22A), RM ANOVA showed a significant effect of treatment (F4,28=42.52, 
p<0.0001), but not time (F1,37=0.05, p=0.82), and a significant time X treatment interaction 
(F4,37=5.23, p=0.0019) at the contralateral paw. RM ANOVA at the ipsilateral paw led to similar 
results, namely a significant effect of treatment (F4,28=16.43, p<0.0001), but not time (F1,37=1.32, 
p=0.26) or time X treatment interaction (F4,37=2.08, p=0.10). Post hoc analysis at 20 min after 
injection revealed that SNC-80 dose-dependently reduced the immobility time at both the 
contralateral and ipsilateral paws (~89% and ~85%, respectively with highest dose tested; Fig. 
22A). Threshold dose was 1 mg/kg and maximal effect was observed with 10 mg/kg. SNC-80 
effect persisted up to 70 min but was larger at the contralateral paw.  
RM ANOVA showed an overall effect of SNC-80 on the contralateral paw (Fig. 22B) when 
performed in the drag test (F4,32=26.45, p<0.0001). However no effect of time (F1,44=1.09, 
p=0.30) or time X treatment interaction (F1,44=1.02, p=0.40) were seen. The number of steps 
made with the contralateral paw was increased in a prolonged fashion by SNC-80,  the 1 mg/kg 
dose being the threshold. Maximal increase was observed at 10 mg/Kg SNC-80 (~154%). No 
change was observed at the ipsilateral paw (Fig. 22B). 
 RM ANOVA on time spent on the rotarod (Fig. 22C) showed an overall effect of SNC-80 
(F4,28=29.91, p<0.0001) but no effect of time (F1,33=0.90, p=0.35) or a time X treatment 
interaction (F4,33=0.64, p=0.63). Post hoc analysis at 20 min revealed an increase in rotarod 
performance with at 3 mg/kg (~62%) and 10 mg/kg (~101%) SNC-80 (Fig. 22C).  This effect 
persisted at 70 min following treatment. 
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Fig 22. Effect of systemic administration of the nonpeptide DOP receptor agonist SNC-80 (0.1-10 mg/kg, 
i.p.) in the bar (A) drag (B) and rotarod (C) tests. Each experiment consisted of three different sessions: a 
control session followed by other two sessions performed 20 and 70 min after vehicle or SNC-80 
administration (see Methods). Data are expressed as percentages of basal motor activity in the control 
session and are means ± SEM of 8-10 determinations per group. Basal motor activity in the bar test was 
(sec) 19.4 ± 1.8 (ipsilateral paw) and 35.0 ± 2.2 (contralateral paw). Basal motor activity in the drag test 
was (number of steps) 10.7 ± 0.3 (ipsilateral paw) and 2.1 ± 0.1 (contralateral paw). Rotarod performance 
was 540 ± 40 sec (0-55 rpm range).   
*p<0.05, **p<0.01, significantly different from vehicle (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s 
test). 
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4.2.2 Effects of the DOP receptor antagonist NTD on motor behavior   
To unravel tonic influence of DOP receptors on motor activity the DOP receptor antagonist NTD 
was given systemically. NTD (0.1-5 mg/kg) dose-dependently impaired motor behavior in all 
tests performed.  
In the bar test (Fig. 23A), RM ANOVA showed a main effect of treatment (F3,15=5.55, 
p=0.0091) but not time (F1,18=0.62, p=0.43), and a significant time X treatment interaction 
(F3,18=3.22, p=0.047) at the contralateral paw. Post hoc analysis revealed that NTD increased 
immobility time at 5 mg/kg (~78%), although a delayed effect was observed also with 1 mg/kg 
(Fig. 23A). RM ANOVA at the ipsilateral paw showed a significant effect of treatment 
(F3,15=15.15, p<0.0001) but not time (F1,18=4.37, p=0.051) or a time X treatment interaction 
(F3,18=1.61, p=0.22). NTD produced a robust elevation in immobility time at 5 mg/kg both at 20 
and 70 min after injection (Fig. 23A).  
RM ANOVA on the number of steps at the contralateral paw (Fig. 23B) showed an overall effect 
of NTD (F3,15=22.11, p<0.0001) but not time (F1,18=1.13, p=0.30), and a significant time X 
treatment interaction (F3,18=3.16, p=0.049). NTD 1 and 5 mg/kg produced significant decreases 
in stepping activity both at 20 min (~37% and ~45%, respectively) and 70 min (~24% and ~52%, 
respectively) after administration (Fig. 23B). A delayed decrease in stepping was also detected 
with the lowest 0.1 mg/kg dose (~28%). No effect was seen in the ipsilateral paw in the drag test 
(Fig. 23B). 
 RM ANOVA showed an overall effect of treatment in the rotarod test (F3,15=27.47, p<0.0001) 
though no effect of time (F1,18=0.29, p=0.59) or a time X treatment interaction (F3,18=1.41, 
p=0.27) were detected (Fig. 23C). Post hoc analysis revealed that NTD decreased rotarod 
performance at 5 mg/kg both at 20 min (~40%) and 70 min (~55%) after treatment (Fig. 23C). A 
delayed reduction in rotarod performance was also observed at  0.1 mg/kg (~25%) and 1 mg/kg 
(~34%) doses 70 min after treatment (Fig. 23C).   
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Fig 23. Effect of systemic administration of the DOP receptor antagonist naltrindole (NTD; 0.1-5 mg/kg, 
i.p.) in the bar (A)  drag (B) and rotarod (C) tests. Each experiment consisted of three different sessions: a 
control session followed by other two sessions performed 20 and 70 min after vehicle or NTD 
administration (see Materials and Methods). Data are expressed as percentages of basal motor activity in 
the control session and are means ± SEM of 6 determinations per group. Basal motor activity in the bar 
test was (sec) 19.8 ± 2.5 (ipsilateral paw) and 35.2 ± 2.9 (contralateral paw). Basal motor activity in the 
drag test was (number of steps) 10.2 ± 0.7 (ipsilateral paw) and 2.4 ± 0.3 (contralateral paw). Rotarod 
performance was 600 ± 32 sec (0-55 rpm range).   
*p<0.05, **p<0.01, significantly different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s 
test). 
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Neurochemical Studies 
4.2.3 Effect of systemic administration of DOP receptor ligands on GABA and GLU release in 
GP and SNr 
On the basis of an in vitro study (Maneuf et al., 1994), reduction in GABA release in GP has 
been proposed as the mechanism underlying the antiparkinsonian action of DOP receptor 
agonists. We therefore used microdialysis to monitor amino acid levels following behaviorally 
effective doses of SNC-80 (3 mg/kg). Moreover, NTD (1 and 5 mg/kg) was administered to 
investigate whether endogenous ENK were involved in tonic regulation of GP amino acid levels. 
RM ANOVA revealed a significant effect of treatment (F3,15=16.19, p<0.0001) and time 
(F5,100=4.15, p=0.0018), and a time X treatment interaction (F15,100=3.15 p=0.0003). Post hoc 
analysis revealed that SNC-80 decreased GABA levels compared to vehicle treated animal 
(maximal of ~57%; Fig. 24A). Conversely, NTD (5 mg/kg) evoked a robust increase in 
extracellular GABA levels (~154% at the 30 min time-point) while the lower dose (1 mg/kg) was 
ineffective (Fig. 24A). Additionally, extracellular GLU levels in the GP were not affected by 
SNC-80 or NTD (Fig. 24B). 
Since microdialysis data lend support to the notion that DOP receptor agonists modulate the 
indirect pathway, amino acid levels were also monitored in the ipsilateral SNr, which is a target 
of subthalamonigral GLUergic projections. RM ANOVA on GABA levels revealed a significant 
effect of treatment (F3,12=7.48, p=0.004) but not time (F5,80=1.01, p=0.419) or a time X treatment 
interaction (F15,80=1.36, p=0.187). SNC-80 (3 mg/kg) induced a long-lasting decrease in 
extracellular GABA levels in the SNr with maximal inhibition of ~69% as did NTD (5 mg/kg; 
maximal inhibition of ~54%; Fig. 24C)  Conversely, NTD (1 mg/kg) had no effect. RM ANOVA 
on GLU levels revealed a significant effect of treatment (F3,12=6.41, p=0.0077) but not time 
(F5,80=0.8, p=0.55) or a time X treatment interaction (F15,80=0.67, p=0.80).  SNC-80 was 
effective in evoking a long lasting decrease in extracellular GLU levels (~54%) while NTD had 
no effect at either dose tested (Fig. 24D). 
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Fig 24. Effect of systemic (i.p.) administration (arrow) of behaviorally relevant doses of SNC-80 (3 
mg/kg) and NTD (1 and 5 mg/kg) on extracellular GABA (A-C) and GLU (B-D) levels in SNr. Data are 
means ± SEM of 7 (A-B) or 5 (C-D) experiments per group and are expressed as percent baseline 
(calculated as the mean of the two samples before the treatment). Basal GABA levels in the dialysate 
were 5.0 ± 1.2 (A) and 6.2 ± 1.4 nM (C) while basal GLU levels were 43 ± 7.3 nM (B) and 62.0 ± 8.1 nM 
(D). 
*p<0.05, **p<0.01, significantly different from saline (RM ANOVA followed by contrast analysis) 
 
4.2.4 Effect of regional NTD perfusion on the SNC-80 induced antiakinetic effect 
Although microdialysis data were consistent with an action of DOP receptor agonists at the GP 
level, SNC-80 actions at the nigral or even striatal levels could not be ruled out. Therefore to 
more specifically investigate the regional specificity of the antiakinetic effect of SNC-80, a 
combined microdialysis and behavioral approach was undertaken. Systemic SNC-80 was 
combined with perfusion of NTD, alternatively in SNr, GP or DLS, in order to obtain a region-
selective blockade of DOP receptors. A NTD concentration of 50 nM was chosen since this 
concentration is expected to provide ~5 nM NTD in the surrounding area of the probe (based on 
a ~10% in vitro recovery). Considering the subnanomolar binding affinity of NTD at DOP 
receptors (~0.16-0.25 nM; Rogers et al., 1990, Spetea et al., 1998) and the ~80-fold DOP/KOP 
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and ~330-fold DOP/MOP selectivity (Spetea et al., 1998), 5 nM appears to be a concentration 
selective for DOP receptor blockade.  
RM ANOVA on immobility time at the contralateral paw (Fig. 25A) showed a significant effect 
of treatment (F4,24=27.06, p<0.0001), time (F5,128=3.47, p=0.0056) but not a significant time X 
treatment interaction (F30,128=0.43, p=0.99). Post hoc analysis revealed that 3 mg/kg SNC-80 
evoked a rapid onset and prolonged attenuation of akinesia (~57% reduction with respect to basal 
values; Fig. 25A). NTD perfusion in SNr but not GP or DLS prevented it. Similar data were 
found at the ipsilateral paw (Fig. 25B). RM ANOVA showed a significant effect of treatment 
(F4,24=11.31, p<0.0001), but not time (F5,116=1.37, p=0.24) or a significant time X treatment 
interaction (F30,116=0.42, p=0.99). As for the ipsilateral paw, SNC-80 reduced immobility time, 
this effect again being prevented by SNr but not GP or DLS perfusion of NTD (Fig. 25B). NTD 
perfusion alone in each nucleus did not affect the immobility time at the contralateral or 
ipsilateral paw.  
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Fig 25. Effect of systemic (i.p.) administration (arrow) of a behaviorally effective dose of SNC-80 (3 
mg/kg) while simultaneously perfusing NTD (50 nM, open bar) in SNr, GP or DLS. NTD perfusion 
started 60 min prior to SNC-80 and continued until the end of experiment. Rats were challenged in the bar 
test (described in the Methods) while undergoing microdialysis. Akinesia was evaluated (every 15 min) 
separately at the contralateral (A, n=7) and ipsilateral (B, n=6) forepaws. Data are expressed as mean 
percentages ± SEM of motor activity at basal levels. Basal motor activity in the bar test (sec) was 34.5 ± 
1.4 and 13.1 ± 1.2 at the contralateral and ipsilateral paw, respectively.  
*p<0.05, significantly different from vehicle (RM ANOVA followed by contrast analysis) 
 
 
4.2.5 Effect of regional NTD perfusion on SNC-80 induced neurotransmitter release 
Since the behavioral data pointed to the involvement of nigral DOP receptors in the antiakinetic 
action of SNC-80, we investigated whether NTD perfusion in SNr also prevented the 
neurotransmitter changes induced by SNC-80.  
RM ANOVA on GABA release in SNr (Fig. 26A) showed a significant effect of treatment 
(F3,18=12.55, p<0.0001), time (F5,132=2.83, p=0.0184) and a significant time X treatment 
interaction (F15,132=1.92, p=0.0259). Post hoc analysis showed that SNC-80 reduced nigral 
GABA release (maximal ~46% reduction) and NTD perfusion in SNr prevented it while NTD 
perfusion in GP was without effect (Fig. 26A). Similar results were found for GLU levels (Fig. 
 52
26B). RM ANOVA showed a significant effect of treatment (F3,18=5.71, p=0.0062), time 
(F5,132=2.83, p=0.0184) and a significant time X treatment interaction (F15,132=1.92, p=0.0259). 
SNC-80 reduced GLU levels (maximal ~45% reduction) and intranigral perfusion with NTD 
prevented it. Conversely, NTD perfusion in GP was without effect. NTD perfusion in the SNr or 
GP did not affect amino acid levels in SNr (Fig. 26A-B). 
RM ANOVA on GABA release in GP showed a significant effect of treatment (F3,15=6.37, 
p=0.0053), time (F5,106=8.13, p<0.0001) but not a significant time X treatment interaction 
(F15,106=1.70, p=0.062). Post hoc analysis showed that SNC-80 reduced pallidal GABA release 
(maximal ~48% reduction; Fig. 26C). NTD perfusion in SNr prevented it while NTD perfusion 
in GP attenuated it.  No changes in GLU levels were observed after systemic administration of 
SNC-80 alone or simultaneously with NTD perfusion in SNr or GP (Fig. 26D). 
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Fig 26. Effect of perfusion of naltrindole (NTD) in SNr or GP on nigral and pallidal GABA and GLU 
changes induced by SNC-80. Rats treated (arrow) with vehicle or SNC-80 (3 mg/kg) were simultaneously 
perfused in SNr or GP with NTD (50 nM, open bar). Extracellular GABA and GLU levels in SNr (A-B; 
n=7) and GP (C-D; n=6) were monitored. Data are expressed as means ± SEM of pre-treatment (basal) 
values. Basal GABA and GLU levels (nM) in the dialysate from SNr were 6.5 ± 1.9 and 33.2 ± 3.7, 
respectively, while basal GABA and GLU levels in the dialysate from GP were 4.8 ± 0.8 and 33.8 ± 5.5, 
respectively. 
*p<0.05, **p<0.01, significantly different from vehicle 
#p<0.05, significant difference between drug treated groups (RM ANOVA followed by contrast analysis) 
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Behavioral Studies II 
4.2.6 Effect of SNC-80 microinjections into SNr, GP and DLS on motor behavior 
Microdialysis coupled to the bar test clearly indicated that DOP receptors in SNr were involved 
in the antiakinetic action of SNC-80. To further confirm this view and to also rule out the 
possibility that DOP receptors in GP or DLS modulate motor parameters other than akinesia (e.g. 
bradykinesia), SNC-80 was microinjected (0.1 and 1 nmol) into SNr, GP or DLS and motor 
activity evaluated in the three tests. 
RM ANOVA on immobility time at the contralateral paw following intranigral injection of SNC-
80 (Fig. 27A) showed a significant effect of treatment (F2,12=18.56, p<0.0001), but not time 
(F1,16=0.53, p=0.43) or time X treatment interaction (F2,16=2.47, p=0.11). Post hoc analysis 
revealed that SNC-80 evoked a long-lasting reduction in immobility time at both doses (maximal 
49% at 70 min with 1 nmol; Fig. 27A). RM ANOVA on immobility time at the ipsilateral paw 
also showed a significant effect of treatment (F2,12=8.54, p=0.0049), but not time (F1,16=0.64, 
p=0.53) or time X treatment interaction (F2,16=0.58, p=0.56). SNC-80 evoked a transient 
inhibition (maximal ~36%) of akinesia at the lower 0.1 nmol dose (Fig. 27A).  
RM ANOVA on number of steps at the contralateral paw (Fig. 27B) showed a significant effect 
of treatment (F2,12=10.25, p=0.0025), but not time (F1,16=0.59, p=0.45) or time X treatment 
interaction (F2,16=0.34, p=0.71). SNC-80 increased stepping activity at 0.1 and 1 nmol (to a 
maximal ~58% and ~122%, respectively; Fig. 27B). This effect was also observed after 70 min 
from injection. No change in stepping activity was observed at the ipsilateral paw.  
RM ANOVA on time on the rotarod showed a significant effect of treatment (F2,12=36.46, 
p<0.0001), but not time (F1,16=0.15, p=0.69) or time X treatment interaction (F2,16=0.25, p=0.77). 
SNC-80 dose-dependently improved rotarod performance (~75% and ~147% improvement at 0.1 
and 1 nmol, respectively) when injected in SNr (Fig. 27C). 
Microinjection of SNC-80 in GP or DLS failed to alter motor activity in any of the tests 
performed (Fig. 28). 
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Fig 27. Effect of microinjection of SNC-80 in SNr (0.1 and 1 nmol) in the bar (A) drag (B) and rotarod 
(C) tests. Each experiment consisted of three different sessions: a control session followed by other two 
sessions performed 20 and 70 min after vehicle or SNC-80 microinjection. Data are expressed as 
percentages of basal motor activity in the control session and are means ± SEM of 7 determinations per 
group. Basal motor activity in the bar test was (sec) 25.6 ± 4.6 (ipsilateral paw) and 38.5 ± 4.9 
(contralateral paw). Basal motor activity in the drag test was (number of steps) 10.8 ± 0.4 (ipsilateral paw) 
and 3.2 ± 0.6 (contralateral paw). Rotarod performance was 345 ± 55 sec (0-55 rpm range).   
*p<0.05, **p<0.01, significantly different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s 
test). 
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Fig 28. Effects of microinjection of SNC-80 in GP and DLS (0.1 and 1 nmol in 0.5 µl saline) in the bar 
(A) drag (B) and rotarod (C) tests. Each experiment consisted of three different sessions: a control session 
followed by other two sessions performed 20 and 70 min after vehicle or SNC-80 microinjection (see 
Materials and Methods). Data are expressed as percentages of basal motor activity in the control session 
and are means ± SEM of 7 determinations per group. Basal motor activity in the bar test was (sec) 25.6 ± 
4.6 (ipsilateral paw) and 38.5 ± 4.9 (contralateral paw). Basal motor activity in the drag test was (number 
of steps) 10.8 ± 0.4 (ipsilateral paw) and 3.2 ± 0.6 (contralateral paw). Rotarod performance was 345 ± 55 
sec (0-55 rpm range).   
 
4.2.7 Effect of bicuculline microinjections in GP on motor behavior 
Finally, to confirm that blockade of the striato-pallidal pathway under our experimental 
conditions leads to attenuation of parkinsonism, the GABAA receptor antagonist bicuculline was 
injected in GP at a dose effective in reversing catalepsy in reserpinized rats (1.5 nmol; Maneuf et 
al., 1994).   
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RM ANOVA on immobility time at the contralateral paw following pallidal injection of 
bicuculline (Fig. 29A) showed a significant effect of treatment (F1,4=37.51, p=0.004), time 
(F1,8=8.03, p=0.022) but not a time X treatment interaction (F1,8=4.89, p=0.06). Bicuculline 
evoked a short-lasting reduction in immobility time (~30%) since no effect was seen at the 70 
min time point (Fig. 29A). There was no effect at the ipsilateral paw in this test.  
RM ANOVA on number of steps at the contralateral paw (Fig. 29B) showed a significant effect 
of treatment (F1,4=70.58, p=0.001), but not time (F1,8=3.88, p=0.08), and a significant time X 
treatment interaction (F1,8=5.55, p=0.046). Bicuculline transiently increased stepping activity 
(~54%; Fig. 29B). No change in stepping activity was observed at the ipsilateral paw.  
RM ANOVA on time on rotarod showed a significant effect of treatment (F1,4=15.27, p=0.017), 
time (F1,8=25.68, p=0.001) and a time X treatment interaction (F1,8=22.55, p=0.001). Pallidal 
injections of bicuculline transiently improved rotarod performance (~73%; Fig. 29C). 
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Fig 29. Effects of microinjection of bicuculline in GP (1.5 nmol) in the bar (A) drag (B) and rotarod (C) 
tests. Each experiment consisted of three different sessions: a control session followed by other two 
sessions performed 20 and 70 min after saline or bicuculline microinjection. Data are expressed as 
percentages of basal motor activity in the control session and are means ± SEM of 5 determinations per 
group. Basal motor activity in the bar test was (sec) 19.5 ± 4.7 (ipsilateral paw) and 33.8 ± 7.3 
(contralateral paw). Basal motor activity in the drag test was (number of steps) 11.2 ± 0.5 (ipsilateral paw) 
and 2.6 ± 0.6 (contralateral paw). Rotarod performance was 393 ± 39 sec (0-55 rpm range).  
**p<0.01, significantly different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test) 
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Section III 
The novel delta opioid receptor agonist UFP-512 dually modulates motor activity 
in experimental parkinsonism via control of the nigro-thalamic pathway  
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Behavioral Studies 
4.3.1 Effect of UFP-512 on motor behavior 
To investigate whether UFP-512 could attenuate parkinsonian-like symptoms, it was 
administered systemically over a wide range of doses (0.1-1000 µg/kg i.p.) and motor activity 
evaluated by the drag and rotarod tests.  
RM ANOVA on the number of steps at the contralateral paw in the drag test (Fig. 30A) showed 
an overall effect of treatment (F5,35=12.28, p<0.0001) and time (F1,32=5.03, p=0.031) but not a 
significant time X treatment interaction (F5,32=1.37, p=0.26). Post hoc analysis at 20 min 
revealed that UFP-512 increased the number of steps at 1 and 10 µg/kg (~81% and ~131%, 
respectively; Fig. 30A). This effect was not detected 70 min later and no effect was observed 
with higher doses (i.e. 100 or 1000 µg/kg) at either time point (Fig. 30A). No effect was seen at 
the ipsilateral paw (Fig. 30A).  
RM ANOVA on rotarod time spent on the rotarod (Fig. 30B) showed a significant effect of 
treatment (F5,30=10.81, p<0.0001), but not time (F1,36=1.62, p=0.21), and a significant time X 
treatment interaction (F5,36=3.30, p=0.014). Post hoc analysis at 20 min revealed that UFP-512 
increased motor performance at 1 µg/kg (~63%) and inhibited it at 100 µg/kg (~36%) with no 
effect observed at 70 min following treatment (Fig. 30B).  
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Fig 30. Effect of systemic administration of the novel DOP receptor agonist UFP-512 (0.1-1000 µg/kg 
i.p.) in the drag (A) and rotarod (B) tests. Each experiment consisted of three different sessions: a control 
session followed by other two sessions performed 20 and 70 min after vehicle or UFP-512 administration. 
Data are expressed as percentages of basal motor activity in the control session and are means ± SEM of 7 
determinations per group. Basal motor activity values in the drag test were (number of steps): 10.0 ± 0.4 
(ipsilateral paw) and 2.0 ± 0.1 (contralateral paw). The time spent on the rod (rotarod test) was 499 ± 25 
sec (0-55 rpm range).  
*p<0.05, significantly different from vehicle (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test).  
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Neurochemical Studies 
4.3.2 Effect of UFP-512 on GABA and GLU release in GP 
Motor facilitating and inhibiing doses of UFP-512 were administered and in vivo microdialysis 
was performed to determine how the observed behavioural effects correlated with changes in 
amino acid neurotransmitters (GABA and GLU). 
 RM ANOVA on GABA release in GP (Fig. 31A) showed a significant effect of treatment 
(F2,10=61.84, p<0.0001) but not time (F7,105=0.82, p=0.56), and a significant time X treatment 
interaction (F14,105=4.85, p<0.0001). Post hoc analysis revealed that UFP-512 10 µg/kg caused a 
long-lasting reduction of GABA levels which was significant from 45 min after injection onward 
(maximal ~35% reduction; Fig. 31A). Conversely, UFP-512 1000 µg/kg transiently increased 
GABA levels (maximal ~45%), the effect being significant starting at 30 min after injection (Fig. 
31A).  
Extracellular GLU release was not affected by UFP-512 at either dose tested (Fig. 31B).  
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Fig 31. Effect of systemic (i.p.) administration (arrow) of facilitatory (10 µg/kg) and inhibitory (1000 
µg/kg) doses of UFP-512 on extracellular GABA (A) and GLU (B) levels in GP. Data are means ± SEM 
of 6 (A) or 7 (B) experiments per group and are expressed as percent baseline (calculated as the mean of 
the two samples before the treatment). Basal GABA levels in the dialysate were 3.4 ± 0.4 nM (A) while 
basal GLU levels were 62 ± 9.4 nM (B). 
*p<0.05, significantly different from vehicle (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test).  
 
4.3.3 Effect of UFP-512 on GABA and GLU release in SNr 
RM ANOVA on GABA release in SNr (Fig. 32A) showed a significant effect of treatment 
(F2,10=7.17, p=0.012), time (F7,105=4.88, p<0.0001), and a significant time X treatment 
interaction (F14,105=2.43, p=0.005). Post hoc analysis revealed that UFP-512 10 µg/kg caused a 
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rapid and prolonged decrease in GABA levels (maximal of ~34%) starting 15 min after drug 
injection (Fig. 32A). Also, UFP-512 1000 µg/kg caused a long lasting decrease (maximal ~30% 
reduction) in GABA levels which was somewhat delayed (significant from 45 min; Fig. 32A).  
RM ANOVA on extracellular GLU release in SNr (Fig. 32B) showed a significant effect of 
treatment (F2,10=15.69, p=0.0008), but not time (F7,105=0.35, p=0.93), and a significant time X 
treatment interaction (F14,105=2.76, p=0.0016). Post hoc analysis revealed that UFP-512 10 µg/kg 
caused a transient decrease in GLU levels (maximal ~41%) at 30 and 45 min whereas UFP-512 
1000 µg/kg caused a transient increase (maximal ~43%) at 45 after drug injection (Fig. 32B).  
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Fig 32. Effect of systemic (i.p.) administration (arrow) of facilitatory (10 µg/kg) and inhibitory (1000 
µg/kg) doses of UFP-512 on extracellular GABA (A) and GLU (B) levels in SNr. Data are means ± SEM 
of 6 experiments per group (A and B) and are expressed as percent baseline (calculated as the mean of the 
two samples before the treatment). Basal GABA levels in the dialysate were 4.7 ± 0.5 nM (A) while basal 
GLU levels were 70 ± 6.2 nM (B). 
*p<0.05, significantly different from vehicle (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test).  
 
4.3.4 Effect of UFP-512 on GABA and GLU release in VMTh 
Since the primary output of SNr projects to the thalamus, and this projection is related to normal 
movement activity, we used microdialysis to determine how the observed effect on behavior 
correlated with thalamic amino acid release (GABA and GLU).  
RM ANOVA on GABA release in VMTh (Fig. 33A) showed a significant effect of treatment 
(F2,8=76.42, p<0.0001) but not time (F7,100=0.64, p=0.721), and a significant time X treatment 
interaction (F14,100=3.8, p<0.0001). Post hoc analysis revealed that UFP-512 10 µg/kg caused a 
decrease in GABA levels (maximal ~19% reduction) at 30 and 45 min whereas UFP 1000 µg/kg 
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increased GABA release (maximal ~27% increase) at 30 and 45 minutes after drug injection 
(Fig. 33A).   
RM ANOVA on extracellular GLU release (Fig. 33B) in VMTh showed a significant effect of 
treatment (F2,8=8.54, p=0.01) but not time (F7,92=1.94, p=0.07) and a significant time X treatment 
interaction (F14,92=2.83, p=0.001). Post hoc analysis revealed that UFP-512 10 µg/kg increased 
GLU levels (maximal ~49%) at 30 min whereas UFP 1000 µg/kg was ineffective, although a 
trend to decrease was observed (Fig. 33B).  
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Fig 33. Effect of systemic (i.p.) administration (arrow) of facilitatory (10 µg/kg) and inhibitory (1000 
µg/kg) doses of UFP-512 on extracellular GABA (A) and GLU (B) levels in VMTh. Data are means ± 
SEM of 5-6 (A, B) experiments per group and are expressed as percent baseline (calculated as the mean 
of the two samples before the treatment). Basal GABA levels in the dialysate were 3.6 ± 0.14 nM (A) 
while basal GLU levels were 54 ± 4.4 nM (B). 
*p<0.05, significantly different from vehicle (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
4.3.5 Effect of UFP-512 on akinesia (bar test) while performing microdialysis 
Finally, we correlated the changes in amino acid neurotransmission and akinesia by coupling  
microdialysis to the bar test.  
RM ANOVA on immobility time at the contralateral paw (Fig. 34A) showed a significant effect 
of treatment (F2,8=27.52, p=0.0003) but not time (F7,92=1.25, p=0.283), and a significant time X 
treatment interaction (F14,92=5.03, p<0.0001). Post hoc analysis revealed that UFP-512 10 µg/kg 
caused a transient attenuation of akinesia (~39% reduction with respect to basal values) 30 and 
45 min after injection while UFP-512 1000 µg/kg inversely caused an increase (~39%) in 
immobility time also at 30 and 45 min post injection (Fig. 34A).  
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Similar to the contralateral paw, RM ANOVA on immobility time at the ipsilateral paw (Fig 
34B) showed a significant effect of treatment (F2,8=7.46, p=0.015) but not time (F7,92=1.15, 
p=0.34), and a significant time X treatment interaction (F14,92=2.00, p=0.026). Post hoc analysis 
revealed that UFP-512 10 µg/kg caused a mild and transient attenuation of akinesia (~26%) 45 
min after injection while UFP-512 1000 µg/kg inversely caused an increase (~71%) which was 
significant 15 min after injection (Fig. 34B).  
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Fig 34. Effect of systemic (i.p.) administration (arrow) of a facilitatory (10 µg/kg) or inhibitory (1000 
µg/kg) dose of UFP-512 on the bar test while simultaneously performing microdialysis. Akinesia was 
evaluated (every 15 min) separately at the contralateral (A) and ipsilateral (B) forepaws. Data are 
expressed as percent basal motor activity (calculated as the mean of immobility time in the two sessions 
before treatment) and are means ± SEM of 5-6 determinations per group. Basal motor activity values in 
the bar test were (sec): 11.4 ± 1.4 (ipsilateral paw) and 27.5 ± 1.8 (contralateral paw). 
*p<0.05, significantly different from vehicle (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
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Section IV 
 Combined DOP receptor stimulation and NOP receptor blockade synergistically 
improves motor performance and impairs nigro-thalamic output in experimental 
parkinsonism  
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Behavioral Studies 
4.4.1 The effect of SNC-80 and J-113397 on motor activity 
To investigate whether combined DOP receptor stimulation and NOP receptor blockade caused 
an additive or synergistic effect on the reduction of parkinsonian-like symptoms, SNC-80 and J-
113397 were administered systemically (i.p.) alone or in combination and motor activity 
evaluated in the bar, drag and rotarod tests. The effect  of the subthreshold combination doses 
(SNC 0.1 mg/kg and J-113397 0.1 mg/kg) were investigated first (Fig. 35A-C).  
RM ANOVA showed a significant effect of treatment on the bar test (F3,21=14.0, p<0.0001), but 
not time (F1,22=0.21, p=0.65), or a time X treatment interaction (F3,22=1.32, p=0.29) at the 
contralateral paw. Post hoc analysis revealed that each compound was ineffective alone and that 
only the combination of SNC-80 and J-113397 reduced immobility at the contralateral paw both 
20 min (~37%) and 70 min (~34%) after injection (Fig. 35A). Conversely, no effect was 
observed at the ipsilateral paw.  
Likewise, in the drag test, RM ANOVA at the contralateral paw showed an overall effect of 
treatment at the contralateral paw (F3,27=44.69, p<0.0001) but not time (F1,20=0.02, p=0.89) or 
time X treatment interaction (F3,20=0.34, p=0.79). Post hoc analyisis revealed that only the 
combination of subthreshold doses of SNC-80 and J-113397 caused an improvement in the drag 
test at 20 min (~96%) and 70 min (~98%) after treatment, while each compound alone was 
ineffective (Fig. 35B). No effect was observed at the ipsilateral paw.  
RM ANOVA performed on time spent on the rotarod (Fig. 35C) showed an overall effect of 
treatment (F3,18=16.37, p<0.0001) but not time (F1,16=0.001, p=0.98) or a time X treatment 
interaction (F3,16=0.36, p=0.94). As with the other tests, an increase in rotarod performance was 
only seen with the combination of SNC-80 and J-113397 20 min (~65%) and 70 min (~68%) 
after injection (Fig. 35C).  
Submaximal antiparkinsonian doses of J-113397 (1 mg/kg)  and SNC-80 (3 mg/kg) were then 
tested to determine if their motor enhancing effects could be additive. 
In the bar test (Fig. 35D), RM ANOVA showed a significant effect of treatment (F3,18=14.4, 
p<0.0001), but not time (F1,24=0.06, p=0.81), or a time X treatment interaction (F3,24=1.48, 
p=0.24) at the contralateral paw. At the ipsilateral paw (Fig. 35D), RM ANOVA showed a 
significant effect of treatment (F3,18=4.6, p=0.015), but not time (F1,24=1.81, p=0.19), and a 
significant X treatment interaction (F3,24=4.05, p=0.018). Post hoc analysis revealed that SNC-80 
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reduced immobility at the contralateral paw both 20 (~44%) and 70 min (~32%) after injection 
while it only reduced immobility time (~39%) after 20 min at the ipsilateral paw (Fig. 35D). On 
the other hand, J-113397 did not effect the ipsilateral paw and reduced contralateral paw 
immobility time at 20 min (~23%; Fig. 35D). The combination of SNC-80 and J-113397 
however reduced immobility time at the contralateral paw at 20 min (~38%) and 70 min (~47%) 
as well as at the ipsilateral paw at both 20 (~39%) and 70 min (~41%) following administration 
(Fig. 35D).  
In the drag test (Fig. 35E), RM ANOVA showed an overall effect of treatment at the 
contralateral paw (F3,18=15.47, p<0.0001) but no effect of time (F1,26=3.55, p=0.07) or time X 
treatment interaction (F3,26=2.13, p=0.12). Post hoc analysis revealed that the number of steps 
was increased in a prolonged fashion by both SNC-80 and J-113397 causing a ~28% and ~96% 
increase after 20 min and ~34% and ~55% after 70 min, respectively. The combination of 
submaximal SNC-80 and J-113397 also caused a prolonged increase in the number of steps at 
the contralateral paw at which was not different from that induced by SNC-80 alone (Fig. 35E). 
No effect was seen at the ipsilateral paw in the drag test with SNC-80, J-113397 or their 
combination (Fig. 35E). 
RM ANOVA performed on time spent on the rotarod using submaximal doses (Fig. 35F) showed 
an overall effect of treatment (F3,18=9.36, p=0.0006), but not time (F1,24=1.15, p=0.29) or a time 
X treatment interaction (F3,24=0.66, p=0.59). Post hoc analysis revealed an increase in rotarod 
performance with SNC-80 (~48% and ~36%) and J-113397 (~47% and ~41%) 20 and 70 min 
following treatment, respectively. The combination however caused ~82% and ~105% increases 
20 and 70 minutes after administration, respectively  (Fig. 35F). This increase was greater than 
either drug given alone 70 min after administration, but not 20 min. 
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Fig 35. Effect of systemic (i.p.) administration of SNC-80 and J-113397 alone or in combination on bar 
(A-D), drag (B-E) or rotarod (C-F) tests. Each experiment consisted of three different sessions: a control 
session followed by other two sessions performed 20 and 70 min after vehicle or drug administration (see 
Methods). Data are expressed as percentages of basal motor activity in the control session and are means 
± SEM of 6-10 determinations per group. Basal motor activity values in the bar test were (time spent on 
the bar): 15.9 ± 1.1 (ipsilateral paw) and 27.3 ± 1.6 (contralateral paw). Basal motor activity in the drag 
test was (number of steps) 11.2 ± 0.2 (ipsilateral paw) and 2.1 ± 0.1 (contralateral paw). Rotarod 
performance was 480 ± 23 sec (0-55 rpm range).   
*p<0.05, **p<0.01, significantly different from vehicle  
##p<0.01, significantly different from SNC-80  
§p<0.05, §§p<0.01, significantly different from J-113397 (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s 
test). 
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Neurochemical Studies 
4.4.2 The effect of SNC-80 and J-113397 on GABA and GLU release in GP 
Since behavioral data supported an interaction between DOP receptor stimulation and NOP 
receptor blockade, we sought to determine if neurotransmitter changes in the indirect pathway 
may be responsible. Since the indirect pathway of the BG begins with striatal neurons projecting 
to GP, and excessive pallidal GABA release has been associated with the consequences of DA 
depletion (Gerfen et al., 1991, Maneuf et al., 1994), we performed microdialysis in GP using 
SNC-80 (0.1 mg/kg) and J-113397 (0.1 mg/kg).  
RM ANOVA on GABA release in GP (Fig. 36A) revealed a significant effect of treatment 
(F3,18=4.27, p=0.019) , time (F7,176=6.86, p<0.0001), and a significant time X treatment 
interaction (F21,176=1.86, p=0.016). Post hoc analysis revealed that SNC-80 was ineffective 
whereas both J-113397 and the combination of SNC-80 and J-113397 decreased GABA levels 
compared to vehicle treated animal, (maximal of ~37% and ~21%, respectively; Fig 36A). There 
was no effect of treatment on GLU release (Fig. 36B). 
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Fig 36. Effect of systemic (i.p.) administration of SNC-80 (0.1 mg/kg) and J-113397 (0.1 mg/kg) alone or 
in combination on extracellular GABA (A) and GLU (B) levels in GP. Data are means ± SEM of 6-9 
experiments per group and are expressed as percent baseline (calculated as the mean of the two samples 
before the treatment). Basal GABA levels in the dialysate were 2.9 ± 0.3 nM (A) while basal GLU levels 
were 40 ± 6.0 nM (B). 
*p<0.05, significantly different from vehicle   
#p<0.05, significantly different from SNC-80  (RM ANOVA followed by contrast analysis) 
 
4.4.3 The effect of SNC-80 and J-113397 on GABA and GLU release in SNr 
Since the direct pathway projects from the striatum to SNr and this area is crucial for normal 
motor output, we performed microdialysis there to observe how the combination of DOP 
receptor stimulation and NOP receptor blockade effects nigral neurotransmitter levels. 
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RM ANOVA on SNr GABA levels (Fig. 37A) showed a significant effect of treatment 
(F3,18=16.78, p<0.0001), time (F7,176=5.06, p<0.0001) and a time X treatment interaction 
(F21,176=2.32, p=0.002).  Post hoc analysis revealed that when either SNC-80 (0.1 mg/kg) or J-
113397 (0.1 mg/kg) were given alone there was no effect while the combination of J-113397 and 
SNC-80 evoked a robust increase in extracellular GABA levels (~107% at the 30 min time-point; 
Fig. 37A)  
RM ANOVA on SNr GLU levels (Fig. 37B) showed a significant effect of treatment (F3,18=6.28, 
p=0.004), but not time (F7,160=1.22, p=0.296) and a significant time X treatment interaction 
(F21,160=2.05, p=0.007).  Post hoc analysis revealed that SNC-80 (0.1 mg/kg) given alone had no 
effect,  J-113397 (0.1 mg/kg) caused a transient reduction (maximal ~19% at 45 min) and the 
combination of J-113397 and SNC-80 evoked a sustained decrease (maximal ~30% at 75 min) in 
extracellular GLU levels (Fig. 37B).  
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Fig 37. Effect of systemic (i.p.) administration of SNC-80 (0.1 mg/kg) and J-113397 (0.1 mg/kg) alone or 
in combination on extracellular GABA (A) and GLU (B) levels in SNr. Data are means ± SEM of 6-9 
experiments per group and are expressed as percent baseline (calculated as the mean of the two samples 
before the treatment). Basal GABA levels in the dialysate were 3.0 ± 0.4 nM (A) while basal GLU levels 
were 73 ± 7.5 nM (B). 
*p<0.05, **p<0.01, significantly different from vehicle 
##p<0.01, significantly different from SNC-80  
§§p<0.01, significantly different from J-113397 (RM ANOVA followed by contrast analysis). 
 
4.4.4 The effect of SNC-80 and J-113397 on GABA and GLU release in VMTh  
Since the thalamus is a major target of the SNr, we performed microdialysis there to observe 
how thalamic neurotransmitter release reflect changes in SNr and ultimately motor output. 
RM ANOVA on GABA release in VMTh (Fig. 38A) showed a significant effect of treatment 
(F3,15=9.53, p<0.001), time (F7,108=2.91, p=0.008) and a time X treatment interaction 
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(F21,108=1.81, p=0.026). SNC-80 (0.1 mg/kg) or J-113397 (0.1 mg/kg) given alone had no effect 
while the combination of SNC-80 and J-113397 caused a long lasting decrease (maximal ~25% 
at 75 min) in VMTh GABA release (Fig. 38A).  
RM ANOVA on GLU release in VMTh (Fig. 38B) revealed a significant effect of treatment 
(F3,12=5.86, p=0.01) but not time (F7,112=1.56, p=0.15) and a time X treatment interaction 
(F21,112=2.03, p=0.009). Post hoc analysis revealed that either SNC-80 or J-113397 given alone 
had no effect whereas the combination of SNC-80 and J-113397 caused an increase in VMTh 
GLU release (maximal ~51% at 45 min; Fig. 38B). 
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Fig 38. Effect of systemic (i.p.) administration of SNC-80 (0.1 mg/kg) and J-113397 (0.1 mg/kg) alone or 
in combination on extracellular GABA (A) and GLU (B) levels in VMTh. Data are means ± SEM of 5 
experiments per group and are expressed as percent baseline (calculated as the mean of the two samples 
before the treatment). Basal GABA levels in the dialysate were 4.1 ± 0.4 nM (A) while basal GLU levels 
were 90 ± 6.7 nM (B). 
*p<0.05, significantly different from vehicle 
#p<0.05, significantly different from SNC-80  
§p<0.05, significantly different from J-113397 (RM ANOVA followed by contrast analysis). 
 
4.4.5 Effect of systemic SNC-80 and J-113397 on akinesia (bar) test coupled to microdialysis 
The bar test was performed simultaneously along with microdialysis to investigate the 
physiological meaning of the neurochemical changes described here. This method also allows for 
a more detailed description of the time course of treatment.  
RM ANOVA on time spent on the bar with the contralateral paw (Fig. 39A) showed a significant 
effect of treatment (F3,12=35.01, p<0.0001), time (F7,112=4.99, p<0.0001) and a time X treatment 
interaction (F21,112=6.35, p<0.0001). Post hoc analysis revealed that each drug given individually 
had no effect while the combination of SNC-80 (0.1 mg/kg) and J-113397 (0.1 mg/kg) caused 
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long lasting relief from akinesia with a maximal reduction of ~54% 15 min after administration 
while (Fig. 39A). No effect was seen at the ipsilateral paw with any treatment (Fig. 39B).  
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Fig 39. Effect of systemic (i.p.) administration (arrow) of SNC-80 (0.1 mg/kg), J-113397 (0.1 mg/kg) or 
their combination on the bar test while simultaneously performing microdialysis. Akinesia was evaluated 
(every 15 min) separately at the contralateral (A) and ipsilateral (B) forepaws. Data are means ± SEM of 
5 experiments per group and are expressed as percent baseline (calculated as the mean of the two samples 
before the treatment). Basal motor activity values in the bar test were (time spent on the bar): 19.3 ± 2.1 
(ipsilateral paw) and 30.3 ± 1.6 (contralateral paw).  
**p<0.01, significantly different from vehicle 
##p<0.01, significantly different from SNC-80  
§§p<0.01, significantly different from J-113397 (RM ANOVA followed by contrast analysis). 
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4.4.6 Effect of nigral perfusion of SNC-80 and J-113397 on local GABA and GLU release 
We recently demonstrated that both DOP receptor agonists (Mabrouk et al., 2008) and NOP 
receptor antagonists (Marti et al., 2007) promote locomotion via nigral mechanisms, namely 
through inihbition of nigral-thalamic GABAergic projections. Based on those findings, SNC-80 
(0.01 or 0.1µM) and J-113397 (0.1 or 1 µM) were perfused alone to determine the local effects 
on SNr GABA and GLU release as well as output in the VMTh. The ineffective concentrations 
of SNC-80 and J-113397 were then perfused together to test whether they could induce 
synergistic effects. These experiments were performed in parallel with the bar test to correlate 
neurochemical changes with the alleviation of akinesia.  
RM ANOVA on SNr GABA levels (Fig. 40A) revealed a significant effect of treatment 
(F5,25=7.20, p=0.0003), time (F7,194=8.76, p<0.0001) but not a time X treatment interaction 
(F35,194=1.34, p=0.109). Post hoc analysis revealed that low concentration nigral perfusions of 
SNC-80 (0.01 µM) or J-113397 (0.1 µM) alone had no effect on GABA levels whereas higher 
concentrations (0.1 µM and 1 µM, respectively) increased nigral GABA release by 32% and 
25%, respectively (Fig. 40A). The combination of ineffective concentrations of J-113397 (0.1 
µM) and SNC-80 (0.01 µM) evoked an increase in extracellular GABA levels (maximal ~40%) 
which was similar to that induced by the higher concentrations alone (Fig. 40A).  
RM ANOVA on SNr GLU levels (Fig. 40B) revealed a significant effect of treatment 
(F5,25=14.41, p<0.0001), time (F7,194=8.30, p<0.0001) and a time X treatment interaction 
(F35,194=1.68, p=0.014). Post hoc analysis revealed that low concentrations of SNC-80 or J-
113397 alone had no effect whereas high concentrations of SNC-80 and J-113397 caused 
reductions (maximal ~35% at 75 and ~43% at 45 min, respectively) in GLU release (Fig. 40B). 
The combination of ineffective concentrations of SNC-80 and J-113397 however induced a long 
lasting reduction (maximal ~50% at 90 min) in nigral GLU release which was similar to higher 
concentrations alone (Fig. 40B). 
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Fig 40. Effect of nigral perfusion of SNC-80 (0.01 or 0.1 µM), J-113397 (0.1 or 1 µM) and their 
combinations (SNC-80 0.01 µM with J-113397 0.1 µM or SNC-80 0.1 µM with J-113397 1 µM) on local 
GABA and GLU release. Data are means ± SEM of 5-7 experiments per group and are expressed as 
percent baseline (calculated as the mean of the two samples before the treatment). Basal GABA levels in 
the dialysate were 4.2 ± 0.3 nM (A) while basal GLU levels were 140 ± 14.3 nM (B). 
*p<0.05, **p<0.01, significantly different from vehicle 
##p<0.01, significantly different from SNC-80  
§p<0.05, §§p<0.01, significantly different from J-113397 (RM ANOVA followed by contrast analysis). 
 
4.4.7 Effect of nigral perfusion of SNC-80 and J-113397 on thalamic GABA and GLU release 
To appreciate how the effects observed in the SNr impact nigro-thalamic output neurons, we 
performed microdialysis in VMTh and measured GABA and GLU release.  
RM ANOVA on GABA levels in VMTh showed a significant effect of treatment (F5,25=20.53, 
p<0.0001), time (F7,210=19.60, p<0.0001) and a time X treatment interaction (F35,210=3.92, 
p<0.0001). Post hoc analysis revealed that low concentrations of SNC-80 (0.01 µM) or J-113397 
(0.1 µM) had no effect on thalamic GABA release while higher concentrations of SNC-80 (0.1 
µM) or J-113397 (1.0 µM) reduced it (maximal ~38%, ~26%, respectively; Fig 41A). The 
combination of the ineffective concentrations also produced a reduction in thalamic GABA 
release (~39%) which was similar in magnitude to each of the high concentrations alone (Fig. 
41A).  
 RM ANOVA on VMTh GLU levels (Fig. 41B) revealed a significant effect of treatment 
(F5,25=6.30, p=0.0006), time (F7,194=3.98, p=0.0004) and a time X treatment interaction 
(F35,194=2.20, p=0.0004).  Post hoc analysis revealed that low concentration nigral perfusions of 
SNC-80 (0.01 µM) and J-113397 (0.1 µM) had no effect on thalamic GLU levels whereas the 
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higher concentrations (0.1 µM and 1 µM, respectively) increased them by ~41% (at 60 min) and 
~53% (at 75 min), respectively (Fig. 41B). The combination of J-113397 (0.1 µM) and SNC-80 
(0.01 µM) evoked an increase in extracellular thalamic GLU levels ~52% at 90 min time point 
which was similar in magnitude as the higher concentrations alone (Fig. 41B). 
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Fig 41. Effect of nigral perfusion of SNC-80 (0.01 or 0.1 µM), J-113397 (0.1 or 1 µM) and their 
combinations (SNC-80 0.01 µM with J-113397 0.1 µM or SNC-80 0.1 µM with J-113397 1 µM) on 
thalamic GABA and GLU release. Data are means ± SEM of 5-7 experiments per group and are 
expressed as percent baseline (calculated as the mean of the two samples before the treatment). Basal 
GABA levels in the dialysate were 5.6 ± 0.3 nM (A) while basal GLU levels were 77 ± 6.4 (B).  
*p<0.05, **p<0.01, significantly different from vehicle 
#p<0.05, ##p<0.01, significantly different from SNC-80  
§p<0.05, §§p<0.01, significantly different from J-113397 (RM ANOVA followed by contrast analysis). 
 
4.4.8 Effect of nigral perfusion of SNC-80 and J-113397 on akinesia (bar) test coupled to 
microdialysis 
The bar test was performed simultaneously along with these local perfusion microdialysis studies 
to correlate the alleviation of akinesia with the neurochemical changes described here.  
RM ANOVA on time spent on the bar at the contralateral paw (Fig. 42A) showed a significant 
effect of treatment (F5,20=30.74, p<0.0001), time (F7,168=9.37, p<0.0001) and a time X treatment 
interaction (F35,168=3.11, p<0.0001). Post hoc analysis revealed that at the contralateral paw, low 
concentrations of SNC-80 (0.01 µM) or J-113397 (0.1 µM) did not modify immobility time 
whereas SNC-80 (0.1 µM) and J-113397 (1 µM) reduced time spent on the bar by ~49% and 
~42%, respectively (Fig. 42A). The combination of low concentrations of SNC-80 (0.01 µM) 
and J-113397 (0.1 µM) resulted in long lasting relief from akinesia with a maximal immobility 
time reduction of ~58%, 75 min after administration (Fig. 43A).  
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RM ANOVA on time spent on the bar at the ipsilateral paw (Fig. 42B) showed a significant 
effect of treatment (F5,20=8.32, p=0.0002), time (F7,168=3.78, p=0.0008) and a time X treatment 
interaction (F35,168=1.63, p=0.02). Post hoc analysis revealed that low concentrations of SNC-80 
or J-113397 alone did not have an effect on immobility time whereas high SNC-80 (0.1 µM) and 
J-113397 (1 µM) reduced time spent on the bar by ~31% and ~34%, respectively (Fig. 42B). The 
combination of low concentrations of SNC-80 (0.01 µM) and J-113397 (0.1 µM) also caused a 
reduction (maximal ~48% at 75 min) in immobility time similar to the effect seen with either 
drug given alone at high concentrations (Fig. 43B). 
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Fig 42. Effect of nigral perfusion of SNC-80 (0.01 µM or 0.1 µM), J-113397 (0.1 µM or 1 µM) or of 
combination of SNC-80 (0.01 µM) and J-113397 (0.1 µM) on the bar test while undergoing 
microdialysis. Akinesia was evaluated (every 15 min) separately at the contralateral (A) and ipsilateral 
(B) forepaws. Data are means ± SEM of 5 experiments per group and are expressed as percent baseline 
(calculated as the mean of the two samples before the treatment). Basal motor activity values in the bar 
test were (time spent on the bar): 11.1 ± 0.7 (ipsilateral paw) and 26.6 ± 1.0 (contralateral paw).  
*p<0.05, **p<0.01, significantly different from vehicle 
#p<0.05, ##p<0.01, significantly different from SNC-80  
§p<0.05, §§p<0.01, significantly different from J-113397 (RM ANOVA followed by contrast analysis). 
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5. DISCUSSION 
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Section I. The endogenous MOP receptor agonist Endomorphin-1 dually affects motor activity 
and differentially modulates nigro-striatal and nigro-thalamic pathways. 
This study showed that exogenous EM-1, produced a dose-dependent biphasic regulation of 
spontaneous motor activity and physiologically-stimulated locomotion in rats. Facilitation was 
observed at lower doses (0.1-1 nmol) and inhibition at the higher ones (10 nmol). This effect was 
prevented by the selective MOP receptor antagonist CTOP, thus likely mediated by MOP 
receptors. Moreover, CTOP alone inhibited motor performance, suggesting that tonic activation 
of MOP receptors facilitates motor function. EM-1 and CTOP singularly injected in SNr 
replicated these effects, suggesting that this brain area is primarily involved in the motor 
response.   
EM-1 plays an important role in the control of motor function in rodents not only at rest (Zangen 
et al., 2002, Metha et al., 2001, Bujdoso et al., 2001, 2003) but also during continuous 
movement. The dual control of motor activity induced by administration of EM-1 qualitatively 
reflects the typical action that MOP (but not DOP and KOP) receptor stimulation produces on 
spontaneous locomotion in rats. Facilitation, however, seems to be the predominant since it 
appears at lower doses. Moreover, in keeping with previous finding that naloxone administered 
at MOP-selective doses reduced locomotion in rats (Timar et al., 2005), CTOP also reduced 
motor performance.  
Consistent with an involvement of nigral MOP receptors in motor effects of EM-1, intranigral 
microinjections of morphine (Iwamoto and Way, 1977, 1981, Bontempi and Sharp 1997) or the 
selective MOP receptor agonist DAMGO (Bontempi and Sharp, 1997) induced contralateral 
turning in rats. It is interesting to point out that while unilateral microinjection of 10 nmol i.c.v. 
of the peptide reduced rotarod performance possibly due to an increase in muscular rigidity, 10 
nmol injection in SNr produced initial hyperlocomotion with contralateral bias overcome by 
muscular rigidity. Motor facilitation has been attributed to an increase in nigro-striatal DAergic 
transmission (Iwamoto and Way, 1977, Matsumoto et al., 1988, Bontempi and Sharp, 1997), 
although an alternative non-DAergic mechanism has been suggested (Morelli and Di Chiara, 
1985). Therefore, EM-1 may induce contralateral turning via inhibition of GABAergic 
interneurons in the SNr and subsequent facilitation of the nigro-striatal DAergic transmission 
(Lacey et al., 1989). Excessive striatal DA release may increase muscle tone and rigidity, as 
shown for NOP receptor antagonists (Marti et al., 2004), and impair motor performance. 
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Alternatively, motor inhibiting actions of EM-1 may be due to modulation of nigral GABAergic 
output neurons. Indeed, injection of morphine in SNr produce increased rigidity that did not 
depend on striatal mechanisms but was blocked by intranigral injections of muscimol and 
enhanced by intranigral injections of bicuculline (Turski et al., 1982). These data suggest that 
disinhibition of nigro-thalamic neurons may mediate motor inhibition induced by intranigral 
EM-1. 
It is therefore possible to hypothesize that the biphasic modulation of motor functions by EM-1 
in SNr results from activation of a facilitatory pathway that prevails during a moderate MOP 
receptor activation, followed by recruitment of an inhibitory one that appears during a higher 
degree of receptor activation.  
Important clues on the mechanisms underlying the motor effect of EM-1 came from combined 
microdialysis and behavioral studies. Nigral EM-1 perfusions produced differing effects on 
neurotransmitter release in SNr and target areas (DLS and VMTh) which were dependent on 
concentration and correlated with opposite effects on locomotor activity. In particular, perfusion 
with low EM-1 concentrations reduced thalamic GABA release and facilitated motor activity, 
while perfusion with higher concentrations elevated striatal DA and thalamic GABA release but 
inhibited locomotion. 
Nigral perfusion with EM-1 (0.01 µM) caused a facilitation of local GABA release likely via 
indirect mechanisms. A major source of GABA in SNr is represented by striato-nigral and 
striato-pallidal GABAergic afferents. TTX perfusion in DLS not only reduced spontaneous but 
also attenuated the EM-1-evoked GABA release. This suggests that EM-1 stimulates GABA 
release from striato-nigral terminals. However, simultaneous perfusion of TTX in DLS and SNr 
blocked the facilitation of GABA release. This may be due to the fact that dual TTX perfusion in 
SNr induces a deeper blockade on impulse trafficking along striato-nigral fibers or that other 
intranigral mechanisms contribute to the facilitation of GABA release. In particular, the 
involvement of GABAergic interneurons should be considered in view of the fact that 
bicuculline prevented the effect of low concentrations of EM-1. In fact, raclopride also prevented 
the effect of EM-1. However, since low concentrations of EM-1 did not affect striatal DA 
release, we suggest that DA released from dendrites of SNc DA cells and acting through D2 
receptors plays a permissive role on the effect of EM-1. Whatever the mechanisms, EM-1 
facilitation of nigral GABA release was associated with reduced thalamic GABA release and 
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facilitation of motor activity. Therefore, stimulation of MOP receptors on local interneurons or 
local collaterals extending from nigro-thalamic projections could cause disinhibition of GABA 
release from striato-nigral terminals leading to inhibition of nigro-thalamic projection neurons. 
This event produces thalamic disinhibition and motor activation (Chevalier and Deniau, 1985), 
since it is associated with stimulation of thalamo-cortical GLUergic pathways and motor output 
from cortical areas. The finding that low EM-1 concentrations elevated thalamic GLU release 
(data not shown) is consistent with this view.  
Differently from EM-1 (0.01 µM), EM-1 (1 µM) reduced nigral GABA and elevated thalamic 
GABA release. The inhibitory effect of EM-1 was TTX-insensitive, suggesting a presynaptic 
mechanism of action. However, the reduction in nigral GABA was prevented by co-perfusion 
with bicuculline. Although quite unexpected, this finding may suggest that GABAA receptors 
need to be operative, e.g. play a permissive role, to allow EM-1 inhibition. Interestingly, EM-1 
inhibition of GABA release was independent of DA receptor activation in SNr (raclopride and 
SCH23390-insensitive) but was associated with elevation of striatal DA release, consistent with 
the view that inhibition of GABA release from nigral interneurons disinhibits striatal DA 
transmission (Di Chiara and North, 1982).  Interestingly, motor stimulatory actions of opioids are 
typically associated with increased striatal (accumbal) DA release. This work has demonstrated 
that even with increased striatal DA release, motor inhibition can occur via direct modulation of 
nigro-thalamic output.  
Concluding remarks 
In the present study, we showed that EM-1 produced dual effects on motor activity which were 
dependent on MOP receptor stimulation in SNr. By using microdialysis combined with 
simultaneous motor testing we found that facilitation and inhibition of motor activity were 
associated with inhibition and facilitation of GABA release in the thalamus, respectively. 
Moreover, only motor inhibiting EM-1 concentrations produced increases in striatal DA release. 
These data suggest that EM-1 affects motor activity through modulation of nigro-thalamic 
pathways and challenges the common view that motor stimulation following MOP receptor 
stimulation is mediated only through nigro-striatal DA transmission. 
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Section II. Stimulation of delta opioid receptors located in substantia nigra reticulata but not 
globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats.  
SNC-80 attenuated akinesia/bradykinesia and improved overall gait ability in 6-OHDA 
hemilesioned rats while NTD exerted opposite effects. These findings confirm that DOP receptor 
stimulation, either by synthetic agonists or endogenous ENK, promotes motor function under 
parkinsonian conditions. SNC-80 decreased pallidal GABA as well as nigral GLU and GABA 
release, suggesting an action at the striatal, pallidal or nigral level. However, only NTD perfusion 
in SNr (and not GP or DLS) prevented the antiakinetic effect of SNC-80 and its neurochemical 
correlates. Consistently, microinjections of SNC-80 in SNr (but not GP or DLS) or bicuculline in 
GP replicated the antiparkinsonian effects of systemic SNC-80. These findings challenge the 
common view that DOP receptor agonists attenuate parkinsonism via intrapallidal mechanisms, 
suggesting, instead, that nigral DOP receptors are involved.  
Up-regulation of ENK transmission along the striato-pallidal pathway is thought to play a crucial 
role in maintaining motor function under parkinsonian conditions. To support the view that such 
up-regulation is compensatory in nature (Maneuf et al., 1994), DOP receptor agonists promoted 
movement and attenuated parkinsonian-like motor deficits in rodent and nonhuman primate 
models of PD (Maneuf et al., 1994, Pinna and Di Chiara, 1998, Hudzik et al., 2000, Hill et al., 
2000, Hille et al., 2001). We confirmed the antiparkinsonian potential of DOP receptor agonists 
by using a battery of behavioral tasks providing information on different motor parameters. 
Doses of SNC-80 which would not elicit turning were selected since the sensitivity of the tests 
employed would be disrupted by turning behavior. SNC-80 attenuated akinesia/bradykinesia in 
the bar and drag test comparable to L-DOPA (Marti et al., 2007) although it was more effective 
in improving motor performance and gait ability on the rotarod.  
Previous studies provided the proof-of-concept that DOP receptor agonists have antiparkinsonian 
potential, yet these studies did not parallel behavioral with neurochemical data leaving to 
speculation the circuitry involved and their site of action. We found that systemic administration 
of motor facilitating doses of SNC-80 decreased pallidal GABA release while systemic 
administration of motor inhibiting dose of NTD elevated it. This is in accordance with findings 
that pallidal DOP receptor stimulation inhibits local GABA release in vitro (Dewar et al., 1987; 
Maneuf et al., 1994, Stanford and Cooper 1999) and in vivo (Schroeder and Schneider, 2002), 
and corroborates the notion that activation of presynaptic (Stanford and Cooper, 1999) and/or 
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postsynaptic (Olive et al., 1997) DOP receptors in GP leads to reduced pallidal GABA release 
and motor improvement. However, the combined behavioral and neurochemical analysis clearly 
demonstrated that NTD perfusion in GP attenuated SNC-80 induced inhibition of GABA release 
without having appreciable behavioral consequences. Activation of DOP receptors expressed by 
striato-pallidal neurons (Mansour et al., 1993) or striatal cholinergic interneurons (Le Moine et 
al., 1994) may also directly or indirectly (i.e. by inhibition of tonic cholinergic facilitation; Pisani 
et al., 2003) lead to reduced pallidal GABA release and motor activation. However, DLS 
perfusion with NTD did not change SNC-80 effect, overall suggesting that neither pallidal nor 
striatal DOP receptors contributed to SNC-80 motor actions. Conversely, SNr perfusion with 
NTD prevented both the antiakinetic effect of SNC-80 and its neurochemical correlates, 
indicating that they were mediated by SNr DOP receptors. One could argue that the bar test only 
measures akinesia and that DOP receptors located in GP or DLS may regulate other motor 
parameters. However, microinjections of SNC-80 in GP or DLS also failed to affect motor 
activity in the drag and rotarod test, which are a (gross) measure of bradykinesia and overall gait 
ability. In keeping with this view, intranigral injections of DOP receptors agonists induced 
turning behavior (Jacquet, 1983, Matsumoto et al., 1988) and hyperlocomotion (Morelli et al., 
1989) in naïve rats while pallidal injections were ineffective (Dewar et al., 1985). The failure of 
intrapallidal SNC-80 cannot be attributed to the tests used since blockade of striato-pallidal 
GABAergic transmission via bicuculline injection in GP attenuated parkinsonism, as shown for 
systemic or intranigral SNC-80. The efficacy of intrapallidal bicuculline extends to the 6-OHDA 
hemilesioned rat previous findings in reserpinized rats or MPTP-treated nonhuman primates 
(Maneuf et al., 1994), confirming the pathogenic contribution of striato-pallidal overactivation to 
PD symptoms in this model.  
The ineffectiveness of intrapallidal SNC-80 as well as intrapallidal NTD to block systemic SNC-
80 questions whether pallidal DOP receptors contribute to motor activity under parkinsonian 
conditions. It is possible that, due to up-regulation of striato-pallidal ENK transmission, 
intrapallidal DOP receptors are saturated by endogenous ENK making the contribution of 
exogenous stimulation by SNC-80 irrelevant. Greater DOP receptor saturation by endogenous 
opioids should result in a greater sensitivity to DOP receptor antagonism. Indeed, systemic 
administration of NTD doses selective for DOP receptor blockade (Baker and Meert, 2002, 
Longoni et al., 1991) worsened parkinsonism and increased pallidal GABA release. This 
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endorses the view that ENK tonically sustain motor function under parkinsonian conditions and 
that DOP receptor blockade exacerbates pathogenic GABA release in GP and its inhibitory 
influence on locomotion. However, microdialysis did not reveal neurotransmitter changes in any 
of the areas in which NTD was perfused alone at doses effective in blocking the exogenous 
stimulation. Whether a higher NTD concentration is required to unravel tonic DOP receptor 
modulation in microdialysis studies needs to be investigated. Nevertheless, the finding that DOP 
receptor agonists and antagonists did not produce overall symmetric neurochemical responses 
indicates that they did not act strictly through the same circuits.  
In this respect, it has previously shown that DOP agonists may activate intranigral DA-dependent 
(Morelli et al., 1989) and DA-independent (Matsumoto et al., 1988) mechanisms. SNC-80 could 
activate presynaptic DOP receptors located on GLU nerve terminals (DOP receptor mRNA has 
been detected in STN; Aubert et al., 2007) resulting in reduced excitatory input onto nigro-
thalamic neurons and thalamic disinhibition (Deniau and Chevalier, 1985). Such a mechanism 
underlies the antiakinetic effect of NOP receptor antagonists (Marti et al., 2007). On the other 
hand, SNC-80 could directly reduce firing activity of nigrothalamic neurons, through an action at 
DOP receptors expressed on recurrent collaterals (Rick and Lacey, 1994). Both actions would 
result in reduced nigral GABA release. How stimulation of nigral DOP receptors could cause 
reduction in GABA release in GP appears puzzling, since no nigro-pallidal GABAergic 
projection has been identified thus far. A nigro-pallidal DAergic pathway exists (Fallon and 
Moore, 1978) and pallidal DA inhibits local GABA release via D2 receptors (Floran et al., 1997, 
Raevskii et al., 2003). However, this pathway is impaired to some extent by 6-OHDA lesioning 
(Fuchs and Hauber, 2004, Debeir et al., 2005). Inhibition of GABA release may also reverberate 
changes occurring at the circuitry level. For instance, in keeping with the view that SNC-80 
produces thalamic disinhibition, systemic SNC-80 elevated GLU levels in striatum (data not 
shown), which may result in activation of GABA or cholinergic interneurons (Zackheim and 
Abercrombie, 2005) and inhibition of striato-pallidal neurons.  
Concluding remarks   
The antiparkinsonian potential of DOP receptor agonists has been demonstrated in a number of 
PD models, although lack of simultaneous in vivo neurochemical analysis has left to speculation 
the brain area targeted and circuitry involved. In this study, SNC-80 promoted movement 
through activation of DOP receptors in SNr, challenging the common view that pallidal DOP 
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receptors contribute to antiparkinsonian action of DOP receptor agonists (Maneuf et al., 1994, 
Hill et al., 2000). However, blockade of DOP receptors resulted in worsening of parkinsonism 
and increased pallidal GABA release. Whether endogenous ENK sustain motor function and 
compensate for motor deficits under parkinsonian conditions via activation of pallidal DOP 
receptors requires further investigation. 
 
Section III. The novel delta opioid receptor agonist UFP-512 dually modulates motor activity 
in experimental parkinsonism via control of the nigro-thalamic pathway  
The main finding of this study is that in hemiparkinsonian rats, the novel DOP receptor agonist 
UFP-512 caused opposite changes in motor activity which were dose-related and mirrored by 
changes in GABA release in GP and VMTh as well as GLU release in SNr. In particular, motor 
facilitation was observed at low doses and was associated with a reduction of thalamic GABA 
release while motor inhibition appeared at higher doses and was accompanied by increases in 
thalamic GABA release. These data are consistent with a dual action of UFP-512 on nigro-
thalamic output neurons, possibly leading to opposite changes in thalamo-cortical transmission 
and motor output.  
DOP receptor stimulation has been shown to facilitate locomotion and antiparkinsonian 
behaviors in a number of experimental models of PD (Maneuf et al., 1994, Pinna and Di Chiara, 
1998, Hill et al., 2000, Hille et al., 2001, Mabrouk et al., 2008). In these studies, SNC-80 was 
preferentially used. However, since DOP receptor agonists can lead to different degrees of 
receptor desensitization and signaling pathway recruitment (for a review see Varga et al., 2004), 
it is important to examine the behavioral and neurochemical profiles of different classes of DOP 
receptor agonists in order to develop molecules with antiparkinsonian activity with fewer adverse 
effects (such as tolerance). UFP-512 is a novel pseudopeptide showing high affinity (pKi=10.2) 
for the human recombinant DOP receptor as well as high selectivity over MOP (160-fold) and 
KOP (3500-fold) receptors (Vergura et al., 2007). Compared to SNC-80 in the same tests 
(Mabrouk et al., 2008), UFP-512 appears 1000-fold more potent in stimulating stepping activity 
and rotarod performance (effective doses 1 µg/kg) and as effective as (drag test) or slightly less 
effective (rotarod test) than SNC-80. However, differently from SNC-80, UFP-512 
antiparkinsonian effects appear shorter lasting (no significant change observed at 70 min after 
injection) and lost (or even reversed) at high doses. In past studies, UFP-512 displayed 
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antidepressant and anxiolytic properties in the forced swimming test (Vergura et al., 2008) as 
SNC-80 did (Broom et al., 2002; Saitoh et al., 2004), although it was effective at much lower 
doses both in mice (0.1 mg/kg vs 1 mg/kg, Saitoh et al., 2004) and rats (0.3 mg/kg vs 32 mg/kg, 
Broom et al., 2002). Moreover, UFP-512 failed to affect spontaneous locomotion in mice 
(Vergura et al., 2008) while inconsistent effects have been reported for SNC-80 (Saitoh et al., 
2004; Ito et al., 2008). Interestingly however, UFP-512 reduced immobility time in the mouse 
forced swimming test at 0.1 and 0.3 mg/kg while higher doses (1 mg/kg) were ineffective. 
Analogously in the current study, UFP-512 improved motor behavior at low doses (1-10 µg/kg) 
and depressed it at higher ones (100-1000 µg/kg). The bell-shaped curve cannot be easily 
explained as simple receptor desensitization phenomenon since in vitro studies have shown that 
UFP-512 causes limited densensitization (as measured by the cAMP pathway) of DOP receptors 
as well as significant receptor trafficking (recycling back to cell surface) with respect to other 
DOP agonists such as SNC-80 (Aguila et al., 2007). SNC-80 markedly desensitizes DOP 
receptors with no significant recycling of the receptor to the cell surface but to lysosomes 
following internalization (LeCoq et al., 2004). However, SNC-80 has been tested up to 60 mg/kg 
without causing inhibition of movement in the reserpine-treated rat model of PD (Hill et al., 
2000). In line with this study, SNC-80 dose-dependently facilitated locomotor acitivity in 
hemiparkinsonian rats with no signs of inhibition even at the highest dose tested (10 mg/kg i.p.; 
Mabrouk et al., 2008). It has been reported that DOP receptor agonists bearing the Dmt-tic 
pharmacophore, such as UFP-512, undergo metabolism to form diketopiperazine derivatives 
(Marsden et al., 1993) which are endowed with DOP receptor antagonist characteristics (Balboni 
et al., 1997). In fact, extensive structure-activity studies with this family of pseudopeptides have 
shown that slight chemical modifications may cause agonists to become antagonists (Balboni et 
al., 2008). Since we previously showed that systemic administration of the DOP receptor 
antagonist NTD caused inhibition of motor activity and a worsening of parkinsonism (Mabrouk 
et al., 2008), it is possible that the inverse correlation between dose and effect in the 100-1000 
µg/kg range is due to the progressive build-up of extracellular concentrations of a UFP-512 
metabolite with antagonist properties at the DOP receptor. The recent finding that UFP-512 
behaves as partial agonist at recombinant DOP receptors (T. Costa personal communication) 
lends further support to the hypothesis that the descending portion of the UFP-512 bell-shaped 
curve is due to progressive blockade of DOP receptors. Combined neurochemical and behavioral 
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analysis supported this view and shed light on the circuits involved. A low dose of UFP-512 
reduced GABA release in VMTh and attenuated akinesia while a high dose of UFP-512 caused 
opposite effects. VMTh is one of the main targets of SNr GABA projection neurons, i.e. the 
basal ganglia output, and it has been demonstrated that changes in VMTh GABA release reflect 
changes in nigro-thalamic transmission (Timmerman and Westerink, 1997, Mark et al., 2004, 
Marti et al., 2007). According to the tonic inhibitory role of nigro-thalamic projections on the 
thalamic filter (Deniau and Chevalier, 1985), it is likely that inhibition and facilitation of 
thalamic GABA release results in facilitation and inhibition of thalamo-cortical circuits and 
motor behavior, respectively. It is interesting to note that changes in GABA release in VMTh 
were not mirrored by changes in GLU release. Thus, low UFP-512 doses inhibited GABA and 
facilitated GLU release while high UFP-512 elevated GABA without affecting GLU release. The 
main source of GLU release in VMTh is represented by cortico-thalamic projections (Chevalier 
and Deniau, 1982, McFarland and Haber, 2002) and an increase in thalamic GLU release likely 
reflects activation of cortico-thalamic pathways. Indeed, increased activation of thalamic NMDA 
receptors has been shown to increase locomotion in rats (Klockgether et al., 1986). Alternatively, 
increased GLU release may arise from disinhibition of GLU nerve terminals from an inhibitory 
intrathalamic GABAergic tone (possibly mediated by GABAB receptors; Nyitrai et al., 1999). 
The lack of changes in GLU release following an increase in GABA release may be related to 
the saturation of inhibitory presynaptic GABA receptors caused by tonic activity of nigro-
thalamic neurons. Thus, further increases in nigro-thalamic activity and GABA release would not 
cause GLU inhibition.  
Consistent with that reported for SNC-80 (Mabrouk et al., 2008), motor facilitatory doses of 
UFP-512 also reduced GABA release in GP and SNr. Since perfusion with naltrindole in SNr but 
not GP was able to prevent these changes and associated behaviors, we propose that the 
antiakinetic action of UFP-512, like SNC-80, originates from DOP receptor stimulation in SNr. 
However, this cannot be the case of UFP-512 induced motor inhibition. Indeed, we found that 
both motor inhibiting doses of UFP-512 and naltrindole (Mabrouk et al., 2008) elevated GABA 
release in GP. Since antagonist action can take place only at those receptors activated by 
endogenous agonists, and up-regulation of enkephalin release at striato-pallidal synapses occurs 
as a consequence of DA depletion, it can be speculated that differently from low doses of UFP-
512, high UFP-512 doses impair motor behavior by inhibiting (directly or indirectly) DOP 
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receptors at the pallidal level. Consistent with facilitation of the indirect pathway, high doses of 
UFP-512 increased nigral GLU release. It must be noted, however, that such an effect was not 
observed following naltrindole administration (Mabrouk et al., 2008).  
The finding that both low and high doses of UFP-512 reduced, although with a different time-
course, SNr GABA release is unexpected and quite puzzling. However, it is consistent with that 
previously reported for SNC-80 and naltrindole (Mabrouk et al., 2008) and possibly related to 
dynamic changes in different pools of extracellular GABA. Thus, the effect of low doses may 
reflect a reduction in the activity of nigro-thalamic neurons through an action at DOP receptors 
expressed on recurrent collaterals (Rick and Lacey, 1994). Conversely, the effect of high doses 
may reflect a reduction in the activity in pallido-nigral projections due to marked increase in 
pallidal GABA release. We speculate that the decrease in GABA originating from this specific 
pool together with the increase in nigral GLU would result in increased nigro-thalamic 
transmission and, ultimately, a reduction of motor activity observed in behavioral assays. 
Concluding remarks   
UFP-512 produced opposing motor effects in 6-OHDA hemilesioned rats depending on dose, 
low ones causing facilitation and higher ones causing inhibition. These changes were 
accompanied by inhibition and facilitation of GABA release, respectively, in VMTh suggesting 
that motor changes were due to opposite regulation of nigro-thalamic GABAergic pathway and, 
ultimately, thalamo-cortical transmission and motor output. Although the precise nature of the 
UFP-512 bell-shaped curve remains to be elucidated, the present study suggests that high doses 
of UFP-512 may, directly or indirectly, antagonize DOP receptors. Future studies need to be 
performed to elucidate the pharmacodynamic profile of UFP-512 as well as to isolate, identify 
and pharmacologically characterize UFP-512 degradation products. 
 
Section IV. Combined DOP receptor stimulation and NOP receptor blockade synergistically 
improves motor performance and impairs nigro-thalamic output in experimental 
parkinsonism  
Past studies from our group have demonstrated the importance of opioidergic regulation of 
locomotor activity occurring via nigral mechanisms under parkinsonian conditions. For instance, 
NOP receptor antagonists are capable of reversing motor deficits in 6-OHDA hemilesioned 
(Marti et al., 2005, 2007, 2008) and haloperidol treated (Marti et al., 2004, 2005) rats or MPTP-
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treated mice and nonhuman primates (Viaro et al., 2008). In 6-OHDA lesioned rats, this action 
was associated with decreased nigral GLU and increased nigral GABA release, leading to 
overinhibition of nigro-thalamic projections (Marti et al., 2007, 2008). Recently, we also 
demonstrated that DOP receptor stimulation in SNr enhanced motor activity in hemiparkinsonian 
rats (see section II, Mabrouk et al., 2008). This effect was correlated with a reduction in GLU 
and GABA release in SNr which resulted in reductions of thalamic GABA release (e.g. 
overinhibition of nigro-thalamic input; see section III). Based on our findings and the possibly 
similar mechanisms by which NOP receptor blockade and DOP receptor stimulation influence 
neurotransmission and behavior, we sought to investigate a possible interaction between these 
two receptor types in vivo. The main finding of this study was that systemic administration of 
behaviorally ineffective doses of the selective DOP receptor agonist SNC-80 and the selective 
NOP receptor antagonist J-113397, evoked synergistic attenuation of parkinsonism and 
improvement in motor performance in hemiparkinsonian rats. These effects were mirrored by 
neurochemical changes, since the same doses, ineffective alone, caused a synergistic increase in 
GABA and decrease in GLU release in SNr which was accompanied by a decrease in GABA 
release in VMTh, suggesting that the nigro-thalamic neurons were the neurobiological substrate 
of this interaction. Indeed, the effects on behavior (bar test) and neurochemistry were replicated 
by the co-perfusion of these two compounds in the lesioned SNr, confirming that this brain area 
is where this interaction occurs. These data are consistent with an opposing regulation of nigro-
thalamic output by NOP and DOP receptors and point towards a potential antiparkinsonian 
therapy based on combined administration of NOP receptor antagonists and DOP receptor 
agonists.  
There is solid evidence suggesting that opioid receptors interact both locally (where receptors are 
located in the same tissue on the same or adjacent cells) or nonlocally (in different nuclei; for 
review see Smith and Lee 2003). These interactions may be potentiating or inhibitory and thus 
result in the enhancement or inhibition of signal transduction pathways normally activated by 
either of the receptors alone (Fig. 43, 44). These interactions may also be symmetric or 
asymmetric. Symmetric interactions occur when both receptors affect each other, while 
asymmetric ones occur when only one receptor alters activity of the other. Moreover, when 
receptors are located on the same cell, it is possible for them to physically associate and form 
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dimers which may endow the complex with unique characteristics compared to the single 
receptors alone. 
The NOP receptor has high overlapping mRNA distribution compared to the DOP receptor in the 
CNS (Bunzow et al., 1994). In particular, DOP and NOP receptor binding and mRNA expression 
has been found in SNr (Neal et al., 1999, Cahill et al., 2001), although the anatomical 
localization of these receptors in SNr is mostly unknown leaving to speculation the structures on 
which these receptors act to produce their effects. Despite this, it was reported that SNc DA cells 
express NOP receptors (Norton et al., 2002) and that N/OFQ inhibits the nigro-striatal DAergic 
pathway (Marti et al., 2004). Indeed, stimulation and blockade of NOP receptors in SNr caused a 
decrease and increase of DA release in striatum, respectively (Marti et al., 2004). On the other 
hand, DOP receptors have only been demonstrated on striato-nigral terminals (Abou Khalil, 
1984) while their presence on nigral GABAergic interneurons has been postulated based on the 
finding DA antagonists blocked hyperlocomotion induced by DOP receptor stimulation in SNr 
(Morelli et al., 1989). Indeed, inhibition of GABAergic interneurons would lead to increased 
striatal DA. However, it was never demonstrated that DOP receptor activation in SNr increases 
striatal DA release. Moreover, we have to consider that most nigral DA neurons degenerate after 
6-OHDA lesioning. This makes the possibility that the synergism between DOP receptor 
stimulation and NOP receptor blockade relies on DA mechanisms (i.e. stimulation of residual 
DA neurons) unlikely. The SNr receives a dense innervation of GLU projections from the 
subthalamic nucleus which becomes pathogenically overactive under parkinsonian conditions 
(DeLong, 1990). It was suggested that the antiparkinsonian effect of NOP receptor antagonists, 
such as J-113397, spans from their ability to reduce exaggerated subthalamo-nigral GLUergic 
transmission (Marti et al., 2004, 2005). Indeed in the current study, systemic J-113397 
administration (1 mg/kg) or perfusion in SNr (1 μM) decreased local GLU and increased GABA 
release. One possibility is that J-113397 stimulated a moderate release of GABA by blocking 
endogenous inhibitory N/OFQergic tone on GABAergic interneurons. Blocking this inhibitory 
tone would result in increased nigral GABA levels which may overinhibit subthalamo-nigral 
GLU release. DOP receptor stimulation could target a separate mechanism. Indeed, SNC-80 
could reduce GLU release via stimulation of DOP receptors located on subthalamo-nigral 
terminals. This would lead to reduced excitatory drive onto nigro-thalamic neurons. It is 
interesting to note that we recently showed that systemic administration of SNC-80 at 
 88
behaviorally effective doses (3 mg/kg) decreased nigral GABA yet still maintaining its inhibitory 
effects on GLU release (section II, Mabrouk et al., 2008). This suggests that GLUergic 
mechanisms are primarily responsible for the motor enhancing effects of DOP receptor 
stimulation and that influence over GABA release may be a secondary effect which can be 
altered by indirect non local mechanisms. The discrepancy between the effect of local perfusion 
(increase; present study) and systemic administration (decrease; Mabrouk et al., 2008) of SNC-
80 on nigral GABA release may be explained by the recruitment of inhibitory (possibly extra-
nigral) mechanisms by high dose systemic SNC-80. The effect of lower systemic SNC-80 doses 
should also be investigated. Though the increase in GABA release caused by local perfusion of 
SNC-80 and the enhancement of this effect caused by the combination seems puzzling, it is 
important to understand the complex environment of SNr where GABA pools are derived from 
multiple sources. Local GABAergic interneurons play a crucial part in regulating the output of 
SNr, yet GABAergic projections arrive from striatum, GP and additionally, collaterals on nigro-
thalamic neurons also release GABA. Therefore the increase in nigral GABA release following 
local SNC-80 perfusion cannot be due to monosynaptic DOP receptor stimulation of GABAergic 
structures but likely derives from polysynaptic interactions. The possibility that the synergism 
between SNC-80 and J-113397 occurs via intracellular interaction is also being explored. N/OFQ 
stimulation of NOP receptors co-expressed with MOP receptors on cell lines was shown to blunt 
signaling in response to DAMGO. Accordingly it was demonstrated that the NOP receptor 
antagonist III-BTD blocked heterologous N/OFQ induced phosphorylation of MOP receptors in 
vitro (Ozsoy et al., 2005). Phosphorylation of GPCRs via G-protein kinases is known to be a 
main initiator of desensitization phenomenon since it leads to the uncoupling of G-protein 
effectors from their respective receptors, rendering them inactive. It is also well known that 
selective DOP receptor agonists such as SNC-80 cause significant receptor desensitization 
(Lecoq et al., 2004) which may limit their effectiveness as therapeutic agents. Thus we can 
speculate that the synergism between NOP receptor antagonism and DOP receptor stimulation 
occurs via modulation of DOP receptor desensitization. Supporting this hypothesis is the fact that 
at 70 min following treatment with high doses of SNC-80, motor stimulating effects begins to 
wear off. Moreover, combination of J-113397 with SNC-80 results in a more robust and 
prolonged motor activation. In addition, mRNA of NOP and DOP receptors has been found in 
STN (Neal et al., 1999, Cahill et al., 2001) suggesting the possibility that DOP and NOP 
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receptors are co-expressed on subthalamo-nigral GLUergic projections (see Fig. 44). Therefore, 
NOP receptor blockade may inhibit desensitization pathways which normally occur after DOP 
receptor stimulation leading to a synergistic reduction in GLU release in SNr. Future studies 
focusing on longer time courses of treatment or chronic administration of SNC-80 in the 
presence of J-113397 would be of interest. Whichever the mechanism, ultimately this enhanced 
inhibitory tone of SNr (decreased GLU, and increased GABA) inhibits nigro-thalamic output 
projections, in turn disinhibiting thalamo-cortical projections and thus improving motor 
performance.  
Concluding remarks 
Opioid receptor interactions have been investigated in a variety of disease models in order to 
obtain greater responses or prevent side-effects related to opioid receptor administration. Recent 
in vitro studies by Ozsoy et al (2005) showed that N/OFQ enhanced MOP receptor agonist 
induced phosphorylation via PKC and GRK2 dependent pathways which contribute to the rapid 
desensitization often seen with MOP receptor stimulation. Thus NOP receptor blockade has been 
viewed as an approach to prevent development of tolerance during chronic pain therapy with 
morphine. Also, Mogil and colleagues (1996) demonstrated that NOP receptor stimulation via 
i.c.v. injection of N/OFQ was able to antagonize the antinociceptive effects of the DOP receptor 
agonist DPDPE (i.c.v.), while NOP receptor blockade would potentiate antinociceptive effects of 
morphine. The present study proposes for the first time that combined DOP receptor stimulation 
and NOP receptor blockade may be beneficial in treating PD symptoms. Targeting these two 
opioid receptor subtypes may have additional benefits with respects to each alone in the 
treatment of PD. Indeed, DOP receptor stimulation attenuates 6-OHDA induced cell loss in vivo 
(Borlongan et al., 2000) while indirect evidence that NOP receptor blockade may prevent DA 
cell loss in the MPTP mouse model of parkinsonism has been presented (Marti et al., 2005). 
Thus, a strategy aimed to simultaneously stimulate DOP receptors and inhibit NOP receptors 
may results in additive or synergistic effects on DA cell viability in PD leading to a marked 
neuroprotection. 
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Fig. 43 Possible intercellular interactions between NOP and DOP receptors in SNr. (A) An inhibiting 
assymetic relationship between NOP receptor blockade on inhibitory GABAergic interneurons and 
stimulation of DOP receptors on subthalamo-nigral GLUergic terminals leading to a synergistic reduction 
of GLU release. (B) Symmetric interaction between NOP receptor blockade on inhibitory GABAergic 
interneurons and stimulation of DOP receptors on GABAergic nigro-thalamic axon collaterals, leading to 
synergistic increases in local GABA release followed by further inhibition of nigro-thalamic GLUergic 
projections. Note that (-) refers to inhibition and (+) refers to disinhibition. 
 
Fig. 44 Possible intracellular interactions between opioid receptors in SNr. Blocakde of NOP and 
stimulation of DOP receptors on the same cell may potentiate or attenuate signal transduction pathways 
(arrows) leading to synergistic stimulation (+) or inhibition (-) of the cell. The receptors may physically 
interact (A) or may interact at some point along with signal transduction pathways (B) or they may 
independently act on the cell via different transduction pathways (C).  
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The main findings from this work are that, firstly, the endogenous MOP receptor ligand EM-1 
administered in SNr biphasically controls motor behavior in rats by modulating nigro-thalamic 
neurotransmission. We also showed that the systemic administration of the selective DOP 
receptor agonist, SNC-80, dose dependently improved locomotor activity in hemiparkinsonian 
rats while the DOP receptor antagonist naltrindole worsened it, suggesting that endogenous ENK 
tonically sustain movement under parkinsonian conditions. These effects were found to primarily 
act through nigral mechanisms. We extended our findings with DOP receptors by testing a novel 
DOP receptor agonist UFP-512. Interestingly, depending on dose, we observed both agonistic 
and antagonistic properties leading to motor facilitation and inhibition, respectively.  Those 
studies demonstrated that nigro-thalamic output was strictly correlated with motor behavior 
suggesting that this neuronal population mediates DOP receptor induced changes in motor 
activity. Finally, we discovered an intriguing interaction between the DOP receptor and the NOP 
receptor, namely that stimulation of DOP receptors and blockade in NOP receptors causes a 
synergistic enhancement in locomotor activity and neurotransmitter release. We also 
demonstrated that this effect was mediated in SNr and that nigro-thalamic output was involved.  
The cause of the degeneration of nigral DAergic cells that occurs in PD is unknown. 
Unfortunately, the current treatments available have significant limitations (see section 1.5) and 
do not protect against cell death and therefore new treatments are needed. Interestingly, DOP 
receptor agonists have been shown to promote neurogenesis and have neuroprotective properties. 
This may indicate a potential for DOP receptor agonists in the prevention of neural cell death 
which leads to parkinsonian motor complications. Our studies here concluded that DOP receptor 
agonists influence motor behavior, though probably through mechanisms involving their effects 
on neurotransmission (i.e. reduction of nigral GLU) and not on neural cell proliferation. 
However, the relationship between these 2 phenomena must be further explored. Indeed, an ideal 
therapeutic candidate would, in the short term, improve motor function in PD patients while in 
the long term act to restore degenerated neuronal cells. Additionally, NOP receptor antagonists 
have been shown to restore motor function in a number of animal models of PD and there is 
indirect evidence that they can attenuate MPTP induced neurotoxicity. We demonstrated 
synergistic interactions of these two receptors on their influence over neurotransmitter release 
and locomotor activity, but studies focusing on their interaction relating to their precise 
localization and on neuronal viability must be further explored with molecular approaches. These 
 93
insights contribute to an overall better understanding of the role of opioids in PD and may lead to 
the development or improvement of pharmacological strategies to prevent (with neuroprotective 
opioids) or reduce the severity of the motor complications of the disease alone or in combination 
with more typical DAergic treatments.  
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